0001178913-24-001020 | 20-F | XBRL Viewer

Print Document View Excel Document

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss (Schedule of Cost of Revenues Products) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [abstract]
Salary and benefits (including share-based compensation)	$ 2,703	$ 1,828	$ 2,047
Subcontractors	230	58	190
Depreciation and amortization	672	426	559
Cost of materials	916	636	1,039
Other manufacturing expenses	1,207	779	906
Decrease (increase) in inventory of finished products	(801)	(543)	242
Cost of revenues from sale of products	$ 4,927	$ 3,184	$ 4,983

Balances and Transactions With Related Parties and Key Officers (Schedule of Transactions with Related Parties) (Details)
$ in Thousands

12 Months Ended

Dec. 31, 2023

USD ($)

Directors

Dec. 31, 2022

USD ($)

Directors

Dec. 31, 2021

USD ($)

Directors

Disclosure of transactions between related parties [line items]

Professional Fee

$ 527

$ 547

$ 460

Number of Directors | Directors

^[1]

^[2]

Directors [Member]

Disclosure of transactions between related parties [line items]

Professional Fee

$ 502

$ 484

$ 375

Related Party [Member]

Disclosure of transactions between related parties [line items]

Professional Fee

$ 267

$ 457

$ 469

[1]	During 2023 three members of the board have left and one member of the board was replaced. At the end of 2023, the total board member consisted of five members.
[2]	During 2022 two members of the board of directors were replaced.

Intangible Assets, Net

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about intangible assets [abstract]

Intangible Assets, Net

Note 12:

Intangible Assets, Net

	License and Knowhow
	2023		2022
Cost
Balance as of January 1,		1,538		1,538
Additions		-		-
Balance as of December 31,		1,538		1,538
Accumulated Amortization
Balance as of January 1,		1,307		1,241
Additions		66		66
Balance as of December 31,		1,373		1,307
Amortized cost
Balance as of December 31,		165		231

Intangible assets include exclusive licenses to use patents, know-how and intellectual property for the development, manufacturing and marketing of products related to burn treatments and other products in the field of wound care. These licenses were purchased from third parties and from one of the Company's shareholders.

Liabilities in Respect of IIA Grants (Schedule of israeli innovation authority grants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of israeli innovation authority grants [Abstract]
Balance as of January 1	$ 7,566	$ 8,105
Royalties	(190)	(407)
Amounts carried to Profit or Loss	427	(132)
Balance as of December 31	7,803	7,566
Current maturities	(126)	(121)
Long term liabilities in respect of IIA grants	$ 7,677	$ 7,445

Material Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Disclosure of significant accounting policies [Abstract]

Basis of consolidation

Basis of consolidation:

Consolidated financial statements include the financial statements of companies that the Company controls (subsidiaries). Control is achieved when the Company is exposed, or has rights, to variable returns from its investment with the investee and has the ability to affect those returns through its power over the investee.

The financial statements of the Company and its subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all entities in the Group.

Inventories

Inventories:

Inventories are measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated selling costs. The Company periodically evaluates the condition and age of inventories and makes provisions for slow moving inventories accordingly.

Cost of inventories is determined as follows:

Raw materials	-	At cost of purchase using the first-in, first-out method.
Finished goods	-	On the basis of average standard costs (which approximates actual cost on a weighted average basis) including materials, labor and other direct and indirect manufacturing costs based on practical capacity.

Property, plant and equipment, net

Property, plant and equipment, net:

Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation and accumulated impairment losses. Cost includes spare parts and auxiliary equipment that are used in connection with the plant and equipment.

Depreciation is calculated on a straight‑line basis over the useful life of the assets at annual rates as follows:

		%
Office furniture		7-10
Manufacturing machinery and lab equipment		15-33
Computers		33
Leasehold improvements		See below

Leasehold improvements are depreciated on a straight‑line basis over the shorter of the lease term (including the renewal option held by the Company which is expected to be exercised) and the expected life of the improvement.

The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate.

Liability in respect of Israeli Innovation Authority ("IIA")

Liability in respect of Israeli Innovation Authority ("IIA"):

Grants from the IIA in respect of research and development projects are accounted for as forgivable loans according to IAS 20. Grants received from the IIA are recognized as a liability according to their fair value on the date of their receipt, unless on that date it is reasonably certain that the amount received will not be refunded. If future economic benefits are expected from the project that will result in royalty-bearing revenues from sale of products it will be treated as a contingent liability.

At the end of each reporting period, the Company evaluates whether there is reasonable assurance that the liability recognized, in whole or in part, will not be repaid based on its best estimate of future sales and any changes in the present value of the cash flows discounted at the original interest rate of the grant are recognized in profit or loss. The difference between the amount received and the fair value on the date of receiving the grant is recognized as a deduction of research and development expenses.

Leases

Leases:

The Company accounts for a contract as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.

For these excluded leases, the Company has elected to recognize the lease payments as an expense in profit or loss on a straight-line basis over the lease term. In measuring the lease liability, the Company has elected to apply the practical expedient in the Standard and does not separate the lease components from the non-lease components (such as management and maintenance services, etc.) included in a single contract.

Following are the amortization periods of the ROU assets by class of underlying asset:

		Years
Motor vehicles		3
Buildings		6-15

The Company tests for impairment of the ROU asset whenever there are indications of impairment pursuant to the provisions of IAS 36.

•

Variable lease payments that depend on an index:

On the commencement date, the Company uses the index rate prevailing on the commencement date to calculate the future lease payments.

For leases in which the Company is the lessee, the aggregate changes in future lease payments resulting from a change in the index are discounted (without a change in the discount rate applicable to the lease liability) and recorded as an adjustment of the lease liability and the ROU assets, only when there is a change in the cash flows resulting from the change in the index (that is, when the adjustment to the lease payments takes effect).

•

Lease extension and termination options:

A non-cancelable lease term includes both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.

Revenues recognition

Revenues recognition:

The Company recognizes revenue when the customer obtains control over the promised goods or services. The revenue is measured according to the amount of the consideration to which the Company expects to be entitled in exchange for the goods or services promised to the customer, other than amounts collected for third parties.

The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract.

Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied.

The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. Amounts received, or that are unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract are recognized as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as the current portion of deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

The Company’s revenue-generating arrangements typically include licensing arrangements, which comprise of upfront license fees, milestone payments and/or royalties and products sale arrangements.

The promised goods or services in the Company’s licensing arrangements typically consist of a license to the Company’s intellectual property and/or research and development services.

If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

In 2019, the Company entered into exclusive license and supply agreements with Vericel to commercialize Nexobrid in North America (see Note 22). The Company identified three distinct performance obligations: (1) license rights (2) development services for BLA approval and (3) manufacturing and supply of Nexobrid.

As of the closing date of the agreement the manufacturing and development services were at market value, therefore the upfront payment was fully attributed to the license performance obligation and as such revenues are recognized at the point in time that control of the license is transferred to the customer.

Future milestone payments are considered variable consideration and are subject to the variable consideration constraint, i.e. will be recognized once concluded that it is “probable” that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable considerations are resolved. (see Note 18b).

Revenues from royalties under this agreement will be payable based on future commercial sales, up on an occurrence.

Revenues from the sale of products to Vericel will be recognized when all the significant risks and rewards of ownership of the products have passed to the buyer and the seller no longer retains continuing managerial involvement. The delivery date of the products is usually the date of which ownership passes.

Revenues from distribution licensing arrangements:

The Company accounts for the bundled license provided to the distributers and related high specialized services as a single performance obligation and consequently recognize revenue using the cost-to-cost method, where the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected to be incurred upon satisfying such single performance obligation. The revenues from such bundled performance obligation are included within “Revenues from license agreements”. Significant finance components related to such arrangements are recognized as finance expense.

Revenues from development services:

Revenues from development services are recognized over time, during the period the customer receives and consumes the benefits provided by the Company's performance.

Revenues from the sale of products:

The Company generates revenues from sales of its innovative biopharmaceutical product, Nexobrid, to burn centers and hospital burn units in Europe, U.S Israel and local international markets through its commercial organizations and local distributors.

Revenues from sale of goods is recognized in profit or loss at the point in time when the control of the goods is transferred to the customer, generally upon delivery of the goods to the customer. The transaction price is the amount of the consideration that is expected to be received based on the contract terms.

Research and development expenses

Research and development expenses:

Research and development expenses are recognized in profit or loss when incurred. An intangible asset arising from a development project or from the development phase of an internal project is recognized if the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company's intention to complete the intangible asset and use or sell it; the Company's ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; the availability of adequate technical, financial and other resources to complete the intangible asset; and the Company's ability to measure reliably the expenditure attributable to the intangible asset during its development. Since the Company's research and development projects are often subject to regulatory approval procedures and other uncertainties, the conditions for the capitalization of costs incurred before receipt of approvals are not normally satisfied and, therefore, research and development expenses are recognized in profit or loss when incurred.

Financial instruments

Financial instruments:

The accounting policy for financial instruments in accordance with IFRS 9, "Financial Instruments" ("the Standard") is as follows:

Financial liabilities:

Financial liabilities measured at amortized cost:

Financial liabilities are initially recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.

After initial recognition, the Company measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair value through profit or loss such as derivatives;

Financial liabilities measured at fair value through profit or loss:

At initial recognition, the Company measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.

After initial recognition, changes in fair value are recognized in profit or loss.

Fair value:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

Fair value measurement is based on the assumption that the transaction will take place in the asset's or the liability's principal market, or in the absence of a principal market, in the most advantageous market.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

Warrants

Warrants:

Receipts in respect of warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price or the numbers of shares to be issued are not deemed to be fixed (for example, in case of net share settlement provision), or warrants redemption in cash on the occurrence of Fundamental Transaction the warrants are classified as a non-current derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. The fair value changes are charged to non-operating income and expense on the statement of comprehensive income or loss. Issuance costs allocable to warrants are also recorded as non-operating expense on the statement of comprehensive income or loss.

Provisions

Provisions:

A provision in accordance with IAS 37 is recognized when the Company has a present (legal or constructive) obligation as a result of a past event, it is expected to require the use of economic resources to clear the obligation and a reliable estimate has been made.

Short-term employee benefits and severance pay liability, net

Short-term employee benefits and severance pay liability, net:

The Company has several employee benefit plans:

Short-term employee benefits:

Short-term employee benefits include salaries, paid annual leave, recreation and social security contributions are recognized as expenses as the services are rendered.

Post-employment benefits:

The Company has liabilities for severance pay for its employees in several of jurisdictions and in Israel.

The Company recognizes liability for severance pay mainly due to its employees in EU in accordance with local laws.

Share-based compensation

Share-based compensation:

Certain Company employees and directors are entitled to remuneration in the form of equity-settled share-based compensation.

Equity-settled transactions

The cost of equity-settled transactions with employees is measured at the fair value of their equity instruments granted at grant date. The fair value is determined using the binomial option pricing model.

The cost of equity-settled transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period which the performance or service conditions are to be satisfied, ending on the date on which the relevant employees become fully entitled to the award.

Profit / Loss per share

Profit / Loss per share:

The Company presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the year, adjusted for treasury shares. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders of the Company and the weighted average number of ordinary shares outstanding, after adjustment for treasury shares, for the effects of all dilutive potential ordinary shares, which comprise of warrants, share options and share options granted to employees.

New standards, amendments to standards and interpretations not yet adopted

New standards, amendments to standards and interpretations not yet adopted:

Amendment to IAS 1, Presentation of Financial Statements: "Disclosure of Accounting Policies”

As a result of applying the Amendment, the extent of the accounting policy disclosure provided in the financial statements for 2023 was reduced and adjusted according to the Company’s specific circumstances.

Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current (amendment to IAS 1)

As a result of applying the Amendment the warrants presented in these financial statements (see note 19c), will be classified as a current liability pursuant to the conversion option.

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 11,866	$ 33,895
Short-term and restricted bank deposits	29,842	0
Trade receivables	3,700	9,332
Inventories	2,846	1,963
Other receivables	1,441	650
Total current assets	49,695	45,840
LONG-TERM ASSETS:
Other receivables	233	180
Long-term restricted bank deposits	440	184
Property, plant and equipment, net	9,228	2,366
Right-of-use assets, net	6,698	1,215
Intangible assets, net	165	231
Total non-current assets	16,764	4,176
Total assets	66,459	50,016
Current liabilities [abstract]
Current maturities of long-term liabilities	1,410	2,242
Trade payables and accrued expenses	5,528	5,656
Other payables	3,891	4,159
Total current liabilities	10,829	12,057
Non-current liabilities [abstract]
Warrants, net	7,296	15,606
Liabilities in respect of IIA grants	7,677	7,445
Liabilities in respect of TEVA	2,256	2,788
Non-current lease liabilities	6,350	846
Severance pay liability, net	456	360
Total non-current liabilities	24,035	27,045
Total liabilities	34,864	39,102
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.07 par value: Authorized 20,000,000 shares as of December 31, 2023 and 12,857,143 shares as of December 31, 2022; Issued and Outstanding 9,221,764 shares as of December 31, 2023 and 7,240,020 shares as of December 31, 2022	184	143
Share premium	206,251	178,882
Foreign currency translation reserve	(18)	(5)
Accumulated deficit	(174,822)	(168,106)
Total equity	31,595	10,914
Total liabilities and equity	$ 66,459	$ 50,016

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net loss	$ (6,716)	$ (19,599)	$ (13,551)
Adjustments to profit and loss items:
Depreciation and amortization	1,303	1,272	1,238
Share-based compensation	1,940	1,946	1,673
Revaluation of warrants accounted at fair value	(8,310)	8,977	0
Issuance expenses of warrants through profit and loss	0	1,911	0
Revaluation of liabilities in respect of IIA grants	427	(132)	919
Revaluation of liabilities in respect of TEVA	468	533	590
Financing income and exchange differences of lease liability	257	(109)	188
Increase in severance pay liability, net	83	109	13
Other income	(211)	0	0
Financial income, net	(2,231)	(74)	(11)
Un-realized foreign currency loss (gain)	189	525	(137)
Adjustments to profit and loss items, total	(6,085)	14,958	4,473
Changes in asset and liability items:
Decrease (increase) in trade receivables	5,658	(7,582)	929
Decrease (increase) in inventories	(906)	(721)	257
Decrease (increase) in other receivables	(894)	364	(763)
Increase (decrease) in trade payables and accrued expenses	(594)	414	1,723
Increase (decrease) in other payables	(928)	281	(1,984)
Changes in asset and liability items, total	2,336	(7,244)	162
Net cash used in operating activities	(10,465)	(11,885)	(8,916)
Cash Flows from Investing Activities:
Purchase of property and equipment	(6,464)	(555)	(489)
Interest received	1,947	74	35
Proceeds from (investment in) short term bank deposits, net	(29,804)	0	4,002
Net cash (used in) provided by investing activities	(34,321)	(481)	3,548
Cash Flows from Financing Activities:
Repayment of leases liabilities	(778)	(701)	(693)
Proceeds from exercise of options	0		3
Proceeds from exercise of pre-funded warrants	0	10	0
Proceeds from issuance of shares and warrants, net	24,909	38,380	0
Repayment of IIA grants, net	(380)	(258)	(360)
Repayment of liabilities in respect of TEVA	(834)	(1,667)	0
Net cash provided by (used in) financing activities	22,917	35,764	(1,050)
Exchange rate differences on cash and cash equivalent balances	(160)	(549)	88
Increase (decrease) in cash and cash equivalents	(22,029)	22,849	(6,330)
Balance of cash and cash equivalents at the beginning of the year	33,895	11,046	17,376
Balance of cash and cash equivalents at the end of the year	11,866	33,895	11,046
Supplement disclosure of non-cash transactions:
ROU asset, net recognized with corresponding lease liability	6,825	117	155
Purchase of property and equipment	$ (1,011)	$ 0	$ 0

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of supplementary information to the statements of profit and lost and other comprehensive loss [Abstract]

Schedule of geographical information

	Year ended December 31
	2023		2022		2021

USA (see also Note 18a, 18b, 18c)		13,078		21,872		18,102
EU and other international markets		5,608		4,624		5,661

		18,686		26,496		23,763

Schedule of cost of revenues products

	Year ended December 31
	2023			2022			2021

Salary and benefits (including share-based compensation)		2,703			1,828			2,047
Subcontractors		230			58			190
Depreciation and amortization		672			426			559
Cost of materials		916			636			1,039
Other manufacturing expenses		1,207			779			906
Decrease (increase) in inventory of finished products		(801	)		(543	)		242

		4,927			3,184			4,983

Schedule of cost of revenues services

	Year ended December 31
	2023		2022		2021

Salary and benefits		1,995		1,691		2,003
Subcontractors		8,182		8,138		7,904

		10,177		9,829		9,907

Schedule of cost of revenues license

	Year ended December 31
	2023		2022		2021

Salary and benefits		4		38		102
Royalties payments		-		280		-

		4		318		102

Total Cost of Revenues		15,108		13,331		14,992

Schedule of research expenses

	Year ended December 31
	2023		2022		2021

Salary and benefits (including share-based compensation) (1)		3,148		4,494		2,864
Subcontractors		2,833		4,054		6,323
Depreciation and amortization		396		571		396
Cost of materials		785		572		347
Other research and development expenses		305		490		326

Total Research and development		7,467		10,181		10,256

Schedule of selling expenses

	Year ended December 31
	2023		2022		2021

Salary and benefits (including share-based compensation)		1,991		1,637		1,643
Marketing and consulting		1,637		1,152		627
Depreciation and amortization		50		49		44
Shipping and delivery		356		385		490
Registration and marketing license fees		810		502		584

		4,844		3,725		3,388

Schedule of general expenses

	Year ended December 31
	2023		2022		2021
Salary and benefits (including share‑based compensation)		3,521		3,344		2,905
Professional fees		2,189		2,589		2,480
Depreciation and amortization		185		225		239
Other		873		762		724

		6,768		6,920		6,348

Schedule of financial expense

	Year ended December 31
	2023		2022			2021
Financial income:

Interest income		2,341		270			11
Revaluation of liabilities in respect of IIA grants		-		132			-
Revaluation of Warrants		8,310		-			-
Exchange differences, net		-		59			-

		10,651		461			11
Financial expense:

Revaluation of liabilities in respect of IIA grants		427		-			903
Financing income on net investment in lease		274		102			120
Finance expenses in respect of deferred revenues		8		54			143
Revaluation of liabilities in respect of TEVA		468		533			590
Exchange differences, net		654		-			511
Revaluation of Warrants		-		8,977			-
Issuance expenses of warrants through profit and loss		-		1,911			-
Other		61		60			47

		1,892		11,637			2,314

Financial income (expenses), net		8,759		(11,176	)		(2,303	)

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss (Schedule of Financial Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Financial income:
Interest income	$ 2,341	$ 270	$ 11
Revaluation of liabilities in respect of IIA grants	0	132	0
Revaluation of Warrants	8,310	0	0
Exchange differences, net	0	59	0
Financial income	10,651	461	11
Financial expense:
Revaluation of liabilities in respect of IIA grants	427	0	903
Financing income on net investment in lease	274	102	120
Finance expenses in respect of deferred Revenues	8	54	143
Revaluation of liabilities in respect of TEVA	468	533	590
Exchange differences, net	654	0	511
Revaluation of Warrants	0	8,977	0
Issuance expenses of warrants through profit and loss	0	1,911	0
Other	61	60	47
Financial expense	1,892	11,637	2,314
Financial income (expenses), net	$ 8,759	$ (11,176)	$ (2,303)

Other Payables

12 Months Ended

Dec. 31, 2023

Trade and other payables [abstract]

Other Payables

Note 13:

Other Payables

	December 31
	2023		2022

Employees and payroll accruals		2,109		2,471
Liability in respect of TEVA (see Note 17c)		1,250		417
Related parties		83		307
Deferred revenues		24		63
Other		425		901
		3,891		4,159

Income Tax (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
Income Tax (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Change in tax rate	10%- 25%
Description Of Tax Benefit Period	five to eight years
Limit of benefit entitlement period	12 years
Other Temporary Differences Mainly From R And D Expenses	$ 171,757
Israel [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Income tax rate	23.00%	23.00%	23.00%
Germany [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Income tax rate	29.79%	29.79%	29.79%

Other Payables (Schedule of other payables) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Trade and other payables [abstract]
Employees and payroll accruals	$ 2,109	$ 2,471
Liability in respect of TEVA	1,250	417
Related parties	83	307
Deferred revenues	24	63
Other	425	901
Other payables	$ 3,891	$ 4,159

Net Loss Per Share (Narrative) (Details)		12 Months Ended
Net Loss Per Share (Narrative) (Details)	Sep. 26, 2022 shares	Dec. 31, 2023 shares shares	Dec. 31, 2022 shares shares	Dec. 31, 2021 shares
Earnings per share [line items]
Number of warrants issued	1,082,223	124,491
Number of share options granted		346,950	320,775	53,970
Unregistered pre funded warrants issued		1,407,583
Diluted Weighted Average Number [Member]
Earnings per share [line items]
Number of warrants issued		2,614,297	2,614,297
Number of share options granted		957,487	764,767
Number of restricted share unit issued		32,714	42,013
Unregistered pre funded warrants issued		1,407,583

Leases (Schedule of Disclosures of Right-of-Use Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cost
Balance as of January 1,	$ 2,891	$ 2,921
New leases	6,867	125
Adjustments for indexation	81	83
Disposals	(2,676)	(238)
Balance as of December 31,	7,163	2,891
Accumulated depreciation
Balance as of January 1,	1,676	1,373
Depreciation and amortization	565	539
Capitalized to Leasehold improvements	59
Disposals	(1,835)	(236)
Balance as of December 31,	465	1,676
Depreciated cost
December 31,	6,698	1,215
Buildings [Member]
Cost
Balance as of January 1,	2,341	2,267
New leases	6,460	0
Adjustments for indexation	78	74
Disposals	(2,368)	0
Balance as of December 31,	6,511	2,341
Accumulated depreciation
Balance as of January 1,	1,342	1,028
Depreciation and amortization	334	314
Capitalized to Leasehold improvements	59
Disposals	(1,527)	0
Balance as of December 31,	208	1,342
Depreciated cost
December 31,	6,303	999
Motor vehicles [Member]
Cost
Balance as of January 1,	550	654
New leases	407	125
Adjustments for indexation	3	9
Disposals	(308)	(238)
Balance as of December 31,	652	550
Accumulated depreciation
Balance as of January 1,	334	345
Depreciation and amortization	231	225
Capitalized to Leasehold improvements	0
Disposals	(308)	(236)
Balance as of December 31,	257	334
Depreciated cost
December 31,	$ 395	$ 216

Material Accounting Policies

12 Months Ended

Dec. 31, 2023

Disclosure of significant accounting policies [Abstract]

Material Accounting Policies

Note 3:

Material Accounting Policies

The accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements:

Basis of consolidation:

Inventories:

Cost of inventories is determined as follows:

Raw materials	-	At cost of purchase using the first-in, first-out method.
Finished goods	-	On the basis of average standard costs (which approximates actual cost on a weighted average basis) including materials, labor and other direct and indirect manufacturing costs based on practical capacity.

Property, plant and equipment, net:

Depreciation is calculated on a straight‑line basis over the useful life of the assets at annual rates as follows:

		%
Office furniture		7-10
Manufacturing machinery and lab equipment		15-33
Computers		33
Leasehold improvements		See below

The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate.

Liability in respect of Israeli Innovation Authority ("IIA"):

Leases:

The Company accounts for a contract as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.

Following are the amortization periods of the ROU assets by class of underlying asset:

		Years
Motor vehicles		3
Buildings		6-15

The Company tests for impairment of the ROU asset whenever there are indications of impairment pursuant to the provisions of IAS 36.

•

Variable lease payments that depend on an index:

On the commencement date, the Company uses the index rate prevailing on the commencement date to calculate the future lease payments.

•

Lease extension and termination options:

Revenues recognition:

The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract.

The Company’s revenue-generating arrangements typically include licensing arrangements, which comprise of upfront license fees, milestone payments and/or royalties and products sale arrangements.

The promised goods or services in the Company’s licensing arrangements typically consist of a license to the Company’s intellectual property and/or research and development services.

Revenues from royalties under this agreement will be payable based on future commercial sales, up on an occurrence.

Revenues from distribution licensing arrangements:

Revenues from development services:

Revenues from development services are recognized over time, during the period the customer receives and consumes the benefits provided by the Company's performance.

Revenues from the sale of products:

Research and development expenses:

Financial instruments:

The accounting policy for financial instruments in accordance with IFRS 9, "Financial Instruments" ("the Standard") is as follows:

Financial liabilities:

Financial liabilities measured at amortized cost:

Financial liabilities are initially recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.

Financial liabilities measured at fair value through profit or loss:

At initial recognition, the Company measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.

After initial recognition, changes in fair value are recognized in profit or loss.

Fair value:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

Warrants:

Provisions:

Short-term employee benefits and severance pay liability, net:

The Company has several employee benefit plans:

Short-term employee benefits:

Short-term employee benefits include salaries, paid annual leave, recreation and social security contributions are recognized as expenses as the services are rendered.

Post-employment benefits:

The Company has liabilities for severance pay for its employees in several of jurisdictions and in Israel.

The Company recognizes liability for severance pay mainly due to its employees in EU in accordance with local laws.

Share-based compensation:

Certain Company employees and directors are entitled to remuneration in the form of equity-settled share-based compensation.

Equity-settled transactions

Profit / Loss per share:

New standards, amendments to standards and interpretations not yet adopted:

Amendment to IAS 1, Presentation of Financial Statements: "Disclosure of Accounting Policies”

Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current (amendment to IAS 1)

As a result of applying the Amendment the warrants presented in these financial statements (see note 19c), will be classified as a current liability pursuant to the conversion option.

General (Narrative) (Details) $ / shares in Units, $ in Thousands		1 Months Ended	8 Months Ended	12 Months Ended
	Feb. 07, 2023 USD ($) $ / shares shares	Nov. 28, 2022 ₪ / shares	Oct. 31, 2022 USD ($)	Dec. 31, 2023 ₪ / shares	Dec. 31, 2023 USD ($) shares	May 31, 2023 ₪ / shares	Dec. 31, 2022 ₪ / shares	Dec. 31, 2022 USD ($) shares	Dec. 05, 2022 ₪ / shares
Disclosure of associates [line items]
Number of shares issued \| shares	1,964,286				9,221,764			7,240,020
Par value per share \| (per share)	$ 14	₪ 0.01		₪ 0.07		₪ 0.07	₪ 0.07		₪ 0.01
Retained earnings					$ (174,822)			$ (168,106)
Reverse stock split ratio		1-for-7 ratio		1-for-7 ratio
Gross proceeds	$ 27,500		$ 41,700
Proceeds from issue of ordinary shares	$ 25,469		$ 37,292
Cash and cash equivalents, short-term and restricted bank deposits					$ 41,700

Short-term and restricted bank deposits (Narrative) (Details)	12 Months Ended
	Dec. 31, 2023
Disclosure of financial instruments by type of interest rate [line items]
Period of bank deposits	91-365
Fixed interest rate [Member] \| USD [Member] \| Minimum [Member]
Disclosure of financial instruments by type of interest rate [line items]
Deposit interest rate	6.26%
Fixed interest rate [Member] \| USD [Member] \| Maximum [Member]
Disclosure of financial instruments by type of interest rate [line items]
Deposit interest rate	6.55%

Trade Receivables (Tables)

12 Months Ended

Dec. 31, 2023

Trade and other current receivables [abstract]

Schedule of trade receivables

	December 31
	2023			2022

Vericel (Note 18b)		236			7,500
BARDA (Note 18a)		1,245			701
MTEC (Note 18c)		617			362
Other trade receivables		1,608			771
Less provision for impairment		(6	)		(2	)

		3,700			9,332

Income Tax

12 Months Ended

Dec. 31, 2023

Disclosure Of Income Taxes [Abstract]

Income Tax

Note 21:

Income Tax

The Company operates in two main tax jurisdictions: Israel and Germany. As such, the Company is subject to the applicable tax rates in the jurisdictions in which it conducts its business.

Corporate tax rate in Israel:

The standard tax rate in the years 2021-2023 is 23%.

Benefits under the Law for the Encouragement of Capital Investments:

Tax benefits under the Israel Law for the Encouragement of Capital Investments, 1959 (the "Investment Law"):

Under the Investment Law, the Company has been granted "Beneficiary Enterprise" status which provides certain benefits, including tax exemptions and reduced tax rates. Income not eligible for Beneficiary Enterprise benefits is taxed at a regular rate.

During the benefit period, the Company will be tax exempt in the first two years of the benefit period and subject to tax at the reduced rate of 10%- 25% for an additional period of five to eight years (depending on the percentage of foreign investments in the Company) of the benefit period. The benefit entitlement period starts from the first year that the Beneficiary Enterprise first earned taxable income and is limited to 12 years from the year in which the Company requested to have tax benefits apply. In the event of distribution of dividends from the said tax-exempt income, the amount distributed will be subject to corporate tax at the reduced rate ordinarily applicable to the Beneficiary Enterprise's income.

Tax exempt income generated under the Company's "Beneficiary Enterprise" program will be subject to taxes upon dividend distribution or complete liquidation. The entitlement to the above benefits is conditional upon the Company's fulfilling the conditions stipulated by the Investment Law and regulations published thereunder. Should the Company fail to meet such requirements in the future, income attributable to its Beneficiary Enterprise programs could be subject to the statutory Israeli corporate tax rate and the Company could be required to refund a portion of the tax benefits already received, with respect to such programs.

The principal tax rates applicable to the subsidiary whose place of incorporation is outside of Israel is:

The statutory corporate tax rate in Germany was 29.79% in 2023, 2022 and 2021.

Final tax assessments:

The Company has finalized its tax assessments through the 2016 tax year.

The Company's subsidiary has received the final tax assessment for the year 2021.

Net operating carryforward losses for tax purposes and other temporary differences:

As of December 31, 2023, the Company had carryforward losses and other temporary differences mainly from R&D expenses together amounting to approximately $171,757.

Deferred taxes:

The Company did not recognize deferred tax assets for temporary differences because their utilization in the foreseeable future is not probable.

Current taxes on income:

The Company did not record any current taxes for MediWound Ltd. in Israel for the years ended December 31, 2023, 2022 and 2021 as a result of its carryforward losses.

The current tax expenses are in respect of taxes charged outside of Israel.

Net Loss Per Share (Schedule of Details of Number of Shares and Loss Used in Computation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [abstract]
Weighted average number of shares	9,013,144	4,987,069	3,892,068
Loss	$ (6,716)	$ (19,599)	$ (13,551)

Other Payables (Tables)

12 Months Ended

Dec. 31, 2023

Trade and other payables [abstract]

Schedule of other payables

	December 31
	2023		2022

Employees and payroll accruals		2,109		2,471
Liability in respect of TEVA (see Note 17c)		1,250		417
Related parties		83		307
Deferred revenues		24		63
Other		425		901
		3,891		4,159

Liabilities and Commitments (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of contingent liabilities [line items]
Liabilities	$ 34,864	$ 39,102
Royalty expense	190	407
Third party [Member] \| Patents and intellectual property [Member]
Disclosure of contingent liabilities [line items]
License costs	$ 950
Percentage of royalties to pay for future revenues from sales of products	1.5% to 2.5
Period of royalties to pay for future revenues from sales of products	12 years
One-time lump-sum amount	$ 1,500
Aggregate revenues	100,000
Royalty expense	$ 98	363	$ 149
Third party [Member] \| Patents and intellectual property [Member] \| Sub-licensing of patents [Member]
Disclosure of contingent liabilities [line items]
Percentage of royalties to pay for future revenues from sales of products	10%
Third party [Member] \| Patents and intellectual property [Member] \| Sub-licensing of patents [Member] \| Bottom of range [Member]
Disclosure of contingent liabilities [line items]
Percentage of one-time lump sum payment amount	2.00%
One-time lump-sum amount	$ 1,000
Third party [Member] \| Patents and intellectual property [Member] \| Sub-licensing of patents [Member] \| Top of range [Member]
Disclosure of contingent liabilities [line items]
Percentage of one-time lump sum payment amount	4.00%
Teva [Member]
Disclosure of contingent liabilities [line items]
Revised cash consideration paid		1,000
Obligation for contingent consideration		2,000
Modified contingent consideration		7,200
Liabilities	$ 4,428	4,794
Financial expenses (income)	$ 468	533
R&D Law [Member]
Disclosure of contingent liabilities [line items]
Percentage of royalties to pay for future revenues from sales of products	3
Maximum aggregate royalties paid in percentage	100.00%
Interest rate	12-month interest
Royalty expense		$ 1,942

Balances and Transactions With Related Parties and Key Officers (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2007	Dec. 31, 2022
Chief Executive Officer and Chief Medical Officer [Member]
Disclosure of transactions between related parties [line items]
One-time payments	$ 120	$ 309

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss ( Schedule of Cost of Revenues) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of comprehensive income [abstract]
Salary and benefits	$ 1,995	$ 1,691	$ 2,003
Subcontractors	8,182	8,138	7,904
Cost of revenues from development services	$ 10,177	$ 9,829	$ 9,907

Materials Agreements

12 Months Ended

Dec. 31, 2023

Disclosure Of Material Agreements [Abstract]

Materials Agreements

Note 18:

Materials Agreements

BARDA Contracts

In September 2015, the Company was awarded BARDA Contract for treatment of thermal burn injuries. This contract was amended multiple times to extend its term until September 2024 (the Company is pursuing an extension of the contract) and its total value, up to a total amount of $165,000 as of the end of 2022.

In May 2023 BARDA has awarded an additional approximately $10,000 to the Company. The total amount of the contract is comprised of $110,000 to support research and development activities and up to $65,000 to procure Nexobrid for U.S. emergency preparedness (which will be split between the Company and Vericel following Vericel agreement (see Note 18b)).

As of December 31, 2023, the Company has received approximately $88,282 in funding in the aggregate, from BARDA under the first contract, and an additional $16,500 for procurement of Nexobrid for U.S. emergency preparedness, which were recorded at the net amount of approximately $10,500 following the split of gross profit agreement with Vericel for the initial BARDA procurement.

In September 2018 the Company was awarded the second BARDA contract, to develop Nexobrid for the treatment of Sulfur Mustard injuries as part of BARDA’s preparedness for mass casualty events. The contract provides up to $12,000 of funding to support research and development activities and contains options to provide additional funding of up to $29,000 for additional development activities, animal pivotal studies, and the BLA submission for licensure of Nexobrid for the treatment of Sulfur Mustard injuries. The second BARDA contract expired in 2023. As of December 31, 2023, the Company has received approximately $4,368 of funding from the second BARDA contract.

Vericel Agreement:

On May 6, 2019, the Company entered into exclusive license and supply agreements with Vericel to commercialize Nexobrid in North America (the “Collaboration Agreements”). Pursuant to the Collaboration Agreements, Vericel will obtain the authority over and control of the development, regulatory approval and commercialization of licensed products in the North America territory. MediWound will be responsible for the development of the product through BLA approval, supported and funded by BARDA, as well as the manufacture and supply of Nexobrid. In addition, MediWound retains the commercial rights to Nexobrid in non-North American territory.

Under the terms of the license agreement, Vericel has made an upfront payment to MediWound of $17,500 which was recorded as revenues from license agreements in 2019 as well as an additional milestone payment of $7,500 recorded as revenues from license agreements in 2022 upon BLA approval received in December 2022. Furthermore, Vericel has also agreed to pay MediWound up to $125,000 in payments contingent upon meeting certain annual sales milestones, tiered royalties on net sales ranging from high single-digit to teen-digit percentages, a split of gross profit on committed BARDA procurement orders and a teen-digits royalty on any additional future BARDA purchases of Nexobrid. Under the terms of the supply agreement, Vericel will procure Nexobrid from MediWound at a fixed transfer price.

Total revenue from royalties as of December 31, 2023 was approximately $82.

DOD and MTEC contracts:

On February 17, 2022, the Company was entered into a contract with the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), to develop Nexobrid as a non-surgical solution for field-care burn treatment for the U.S. Army. The contract provides funding up to $2,727.

During 2023, the DOD through MTEC awarded the Company additional funding of $9,117 in addition, the company awarded directly through MTEC funding of $1,190, to advance the development of a new temperature stable formulation of Nexobrid. The total additional fund from the DOD and MTEC during 2023 was $10,307.

Biopharmax Group Ltd. contract:

On July 17, 2023 the company signed a turnkey scale-up agreement with Biopharmax Group Ltd. This strategic agreement is designed to bolster our manufacturing infrastructure to support our long-term growth trajectory. The objective of this agreement is to establish, commission, and validate a cutting-edge, sterile, and GMP-compliant manufacturing facility. The venture aims to increase the company’s production capacity significantly, to expand up to six times the current capacity.

The new facility, equipped with fully operational clean rooms, will be exclusively designed for Nexobrid production. It will comply with stringent regulations from the GMP, FDA, EMA, Israeli Ministry of Health, and relevant Israeli regulatory bodies. An estimated $12.7 million will be invested in the project, set for constructions completion by mid-2024, with full-scale manufacturing expected to commence in 2025 (see also note 10).

Equity (Narrative) (Details)							1 Months Ended		12 Months Ended
Equity (Narrative) (Details)	Feb. 07, 2023 ₪ / shares $ / shares	Feb. 07, 2023 USD ($) $ / shares shares	Oct. 06, 2022 ₪ / shares shares	Sep. 26, 2022 USD ($) shares	Mar. 07, 2022 ₪ / shares	Mar. 07, 2022 USD ($) shares	Nov. 28, 2022 ₪ / shares	Sep. 28, 2022 USD ($)	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2023 ₪ / shares	Dec. 31, 2023 USD ($) shares	May 31, 2023 ₪ / shares shares	Dec. 31, 2022 ₪ / shares shares	Dec. 05, 2022 ₪ / shares shares	Nov. 28, 2022 USD ($) shares	Nov. 27, 2022 USD ($) shares	Sep. 26, 2022 ₪ / shares
Disclosure of classes of share capital [line items]
Additional ordinary shares issued upon vesting of outstanding RSU's									17,458	41,395	4,852
Authorized share capital \| $																	$ 900,000	$ 500,000
Number of shares authorised													20,000,000	1,400,000	12,857,143	90,000,000		50,000,000
Par value per share \| (per share)	$ 14	$ 14					₪ 0.01					₪ 0.07		₪ 0.07	₪ 0.07	₪ 0.01
Reverse stock split ratio							1-for-7 ratio		1-for-7 ratio
Number of common shares issued		1,964,286		1,082,223		744,048
Price per common shares issued \| ₪ / shares	$ 0.0014				₪ 13.44
Proceeds from shares issued \| $		$ 27,500,000				$ 8,653,000
Amount of underwriting discounts and commissions \| $						$ 1,021,000
Exercised options to purchase additional ordinary shares						89,012
Aggregate amount of registered direct offering \| $				$ 13,257,000
Purchase price of registered direct offering \| ₪ / shares																			₪ 12.25
Number of warrants issued				1,082,223					124,491
Exercise price of warrants \| ₪ / shares												₪ 0.0015312							₪ 13.475
Warrants expiration period				4 years
Net proceeds from offering amount \| $								$ 11,698,000
Risk free interest rate of warrants									4.37%
Average standard deviation of warrants									68.00%
Unregistered pre funded warrants issued									1,407,583
Proceeds from warrants \| $									$ 0	$ 10,000	$ 0
Warrants to purchase ordinary Shares									124,491
Commissions and other offering expenses \| $		$ 2,031,000
Increase In Authorized Share Capital														900,000
Increase In Shares Issued																	90,000,000
Private Issuance Purchase Equity Agreement [Member]
Disclosure of classes of share capital [line items]
Proceeds from shares issued \| $									$ 15,920,000
Number of warrants issued			1,407,583
Exercise price of warrants \| ₪ / shares			₪ 0.0013475
Risk free interest rate of warrants									4.26%
Unregistered pre funded warrants issued			1,407,583
Unregistered pre funded warrants to purchase common Stock			1,407,583
Increase in pre funded warrants exercise price \| ₪ / shares			₪ 0.007
Financial liabilities, at fair value \| $													$ 20,788,000
Proceeds from warrants \| $									$ 17,233,000
Loss from warrants transactions \| $													$ 3,555,000
Warrants to purchase ordinary Shares			1,407,583
Certain entities affiliated with CBI [Member]
Disclosure of classes of share capital [line items]
Number of common shares issued						208,334

Cash And Cash Equivalents

12 Months Ended

Dec. 31, 2023

Cash and cash equivalents [abstract]

Cash And Cash Equivalents

Note 4:

Cash and Cash Equivalents

	December 31
	2023		2022

Balance in USD		4,151		24,475
Balance in other currencies		7,715		9,420

		11,866		33,895

Materials Agreements (Narrative) (Details) - USD ($) $ in Thousands			1 Months Ended		12 Months Ended
	May 09, 2023	May 06, 2019	Jul. 17, 2023	Feb. 17, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of contingent liabilities [line items]
Research and development					$ 7,467	$ 10,181	$ 10,256
Revenues net					18,686	26,496	$ 23,763
Biomedical Advanced Research And Development Authority [Member]
Disclosure of contingent liabilities [line items]
License costs						$ 165,000
Additional funding amount	$ 10,000
Accumulated funding					88,282
Research and development	110,000
NexoBrid [Member] \| Biomedical Advanced Research And Development Authority [Member]
Disclosure of contingent liabilities [line items]
Proceeds From Procurement					16,500
Additional funding amount					29,000
Amount of second contract was expired					4,368
Revenues net					10,500
NexoBrid [Member] \| Biomedical Advanced Research And Development Authority [Member] \| Maximum [Member]
Disclosure of contingent liabilities [line items]
Proceeds From Funding					12,000
Proceeds From Procurement	$ 65,000
License Agreement with Vericel [Member]
Disclosure of contingent liabilities [line items]
Upfront payment		$ 17,500
Additional upfront payment		7,500
Revenues net					82
License Agreement with Vericel [Member] \| Maximum [Member]
Disclosure of contingent liabilities [line items]
Additional upfront payment		$ 125,000
Biopharmax Group Ltd. contract [Member]
Disclosure of contingent liabilities [line items]
Amount of invested in the project			$ 12,700
DOD and MTEC contracts [Member]
Disclosure of contingent liabilities [line items]
Proceeds From Funding				$ 2,727
Additional funding amount					9,117
Proceeds From Additional Procurement					1,190
Accumulated funding					$ 10,307

Property, Plant And Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about property, plant and equipment [abstract]

Schedule of property, plant and equipment, net

	Office furniture			Manufacturing machinery and lab equipment		Computers			Leasehold improvements		Total
Cost

Balance as of January 1, 2023		293			5,091		166			3,279		8,829
Additions		25			7,312		101			37		7,475
Capitalization of depreciation of ROU assets		-			-		-			59		59
Foreign currency translation		1			-		-			-		1

Balance as of December 31, 2023		319			12,403		267			3,375		16,364

Balance as of January 1, 2022		257			4,764		176			3,137		8,334
Additions		37			327		49			142		555
Disposals		-			-		(59	)		-		(59	)
Foreign currency translation		(1	)		-		-			-		(1	)

Balance as of December 31, 2022		293			5,091		166			3,279		8,829

Accumulated Depreciation

Balance as of January 1, 2023		157			3,818		97			2,391		6,463
Additions		26			448		58			140		672
Foreign currency translation		1			-		-			-		1

Balance as of December 31, 2023		184			4,266		155			2,531		7,136

Balance as of January 1, 2022		133			3,370		94			2,259		5,856
Additions		25			448		62			132		667
Disposals		-			-		(59	)		-		(59	)
Foreign currency translation		(1	)		-		-			-		(1	)

Balance as of December 31, 2022		157			3,818		97			2,391		6,463

Carrying amounts of all fixed asset items
December 31, 2023		135			8,137		112			844		9,228
December 31, 2022		136			1,273		69			888		2,366

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss (Schedule of General Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [abstract]
Salary and benefits (including share-based compensation)	$ 3,521	$ 3,344	$ 2,905
Professional fees	2,189	2,589	2,480
Depreciation and amortization	185	225	239
Other	873	762	724
General and administrative expenses	$ 6,768	$ 6,920	$ 6,348

Cash And Cash Equivalents (Schedule of cash and cash equivalents) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash and cash equivalents [abstract]
Balance in USD	$ 4,151	$ 24,475
Balance in other currencies	7,715	9,420
Cash and cash equivalents	$ 11,866	$ 33,895	$ 11,046	$ 17,376

Equity (Tables)

12 Months Ended

Dec. 31, 2023

Equity Tables [Abstract]

Schedule of share capital

Share capital:

	December 31
	2023		2022

Authorized number of shares		20,000,000		12,857,143
Issued and outstanding number of shares		9,221,764		7,240,020

Material Accounting Policies (Schedule of amortization periods of right of use assets) (Details)	12 Months Ended
	Dec. 31, 2023
Motor vehicles [member]
Disclosure of quantitative information about right-of-use assets [line items]
Amortization periods of the ROU assets (in years)	3
Building and equipment [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Amortization periods of the ROU assets (in years)	6-15

Liabilities and Commitments

12 Months Ended

Dec. 31, 2023

Disclosure of contingent liabilities [abstract]

Liabilities and Commitments

Note 17:

Liabilities and Commitments

In 2000, the Company signed an exclusive license agreement (as amended in 2007) with a third party with regard to its patents and intellectual property. Pursuant to the agreement, the Company received an exclusive license to use the third party’s patents and intellectual property, for the purpose of developing, manufacturing, marketing, and commercializing products for treatment of burns and other wounds.

The Company paid an aggregate amount of $ 950 and undertook to pay royalties of 1.5% to 2.5% from future revenues from sales of products which are based on this patent for a period of 12 years from the first commercial delivery in a major country, and thereafter the Company will have a fully paid-up royalty-free license for these patents. In addition, royalties will be paid at the rate of 10% from sub-licensing of such patents and for lump sum amounts paid to the Company by a third party, the Company will pay 2% of the proceeds up to $1,000 and 4% above this amount. Moreover, the Company agreed to pay a one-time lump-sum amount of $ 1,500 when the aggregate revenues based on these patents reach $ 100,000. The royalty payments for the years 2021, 2022 and 2023 amounted to $149, $363 and $98 respectively.

Under the Research and Development Law, (the “R&D Law”) the Company undertook to pay royalties of 3% on the revenues derived from sales of products or services developed in whole or in part using IIA grants. The maximum aggregate royalties paid cannot exceed 100% of the grants received by the Company, plus annual interest equal to the 12-month interest applicable to dollar deposits, as published on the first business day of each calendar year. The total royalties amount paid as of December 31, 2023 is $1,942. (Note 14).

In December 2020, Teva has agreed to revise the Settlement Agreement from March 2019, which was comprised of past agreement for collaboration in the development, manufacturing and commercialization of solutions for the burn and chronic wound care markets, as well as the Company’s repurchase of shares from Teva. Under the new settlement the Company paid $1,000 in cash and became obligated to pay an amount of $2,000 over three years and an addition amount of $7,200 in quarterly fixed payments starting 2021 as long as there are revenues generated from sales of Nexobrid.

Total liabilities recorded as of December 31, 2023 and 2022 were approximately $4,428 and $4,794 respectively, and financial expenses of $468 and $533, respectively, were recorded in profit or loss within financial expenses.

Share-Based Compensation (Schedule of Estimated Using Acceptable Option Pricing Models) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Dividend yield (%)	0.00%	0.00%	0.00%
Weighted average share prices (Dollar)	$ 10.71	$ 13.22	$ 36.33
Bottom of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility of the share prices (%)	61.00%	59.00%	55.00%
Risk-free interest rate (%)	2.10%	2.10%	0.10%
Early exercise factor (%)	100.00%	100.00%	100.00%
Top of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility of the share prices (%)	77.00%	77.00%	78.00%
Risk-free interest rate (%)	5.36%	5.20%	1.50%
Early exercise factor (%)	150.00%	150.00%	150.00%

Leases (Schedule of information on leases) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Interest expense on lease liabilities	$ 274	$ 102
Depreciation expenses	565	537
Cash outflow for leases	$ 778	$ 701

General

12 Months Ended

Dec. 31, 2023

Disclosure Of General Information [Abstract]

General

Note 1:

General

Description of the Company and its operations:

MediWound Ltd. Was incorporated in Israel in January 2000. The Company which is located in Yavne, Israel (The "Company" or "MediWound"), is biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic, non-surgical solutions for tissue repair and regeneration. The Company’s strategy leverages its breakthrough enzymatic technology platform into diversified portfolio of biotherapeutics across multiple indications to pioneer solutions for unmet medical needs. The Company’s current portfolio is focused on next-generation protein-based therapies for burn care, wound care and tissue repair.

The Company's first innovative biopharmaceutical product, Nexobrid, has received in December 2022, an approval from the U.S. Food and Drug Administration (“FDA”) and marketing approval in each of India, Switzerland and Japan. In addition, it has a marketing authorization from the European Medicines Agency (“EMA”) and regulatory agencies in other international markets for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns.

The Company commercialize Nexobrid globally through multiple sales channels.

The Company sells Nexobrid to burn centers in the European Union, United Kingdom and Israel, primarily through its commercial organizations.

The Company has established local distribution channels in multiple international markets, focusing on Asia Pacific, EMEA, CEE and LATAM, which local distributors are also responsible for obtaining local marketing authorization within the relevant territories.

In the United States, the Company entered into an exclusive license and supply agreements with Vericel Corporation (“Vericel”) to commercialize Nexobrid in North America upon FDA approval. On September 21, 2023, the Company announced the U.S. commercial availability of Nexobrid® for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns.

On September 20, 2022, The Company announced that EMA has validated for review the Type II Variation to expand the currently approved indication for Nexobrid (removal of eschar in adults with deep partial-and full-thickness thermal burn wounds) into the pediatric population.

The Company’s second investigational next-generation enzymatic therapy product, EscharEx, a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds,

On November 21, 2023 the Company announced in relate to EscharEx clinical trial that an updated Phase III protocol will be submitted during first half of 2024 in accordance with recent discussions with the U.S. FDA and EMA. Study initiation is expected to commence in the second half of 2024.

The Company's securities are listed for trading on NASDAQ since March 2014.

On November 28, 2022, the Company’s shareholders general meeting approved a reverse stock split. Following that approval, on December 5, 2022, the Company’s board of directors approved a reverse stock split, in a range of 1-for-7 ratio. The reverse split went effective on December 20, 2022. (see also Note 19b).

During March, September and October 2022, the Company completed a series of capital public and private offerings. The gross proceeds before deducting underwriting discounts and commissions and offering expenses, were approximately $41,700. The net proceeds were approximately $37,292 (see also Note 19).

On February 7, 2023, the Company completed a registered direct offering. A total of 1,964,286 new ordinary shares were issued in consideration to offering price of $14 per share. The gross proceeds were $27,500, before deducting commissions and other offering expenses. The net proceeds were approximately $25,469.

The Company has three wholly owned subsidiaries: MediWound Germany GmbH, acting as Europe (“EU”) marketing authorization holder and EU sales and marketing arm, and MediWound UK Limited and MediWound US, Inc. which are currently inactive companies.

In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The company’s head quarter, manufacturing and R&D facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. During the year ended December 31, 2023, the impact of this war on the company’s results of operations and financial condition was immaterial.

The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern. From inception to December 31, 2023, the Company has incurred cash outflows from operations, losses from operations, and has an accumulated deficit of $174.8 million.

The Company believes that its existing cash and cash equivalents, short-term and restricted bank deposits of $41.7 million as of December 31, 2023, will be sufficient to fund its operations and capital expenditure for at least twelve months from the date of issuance of these consolidated financial statements.

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about financial instruments [abstract]

Schedule of sensitivity tests relating to changes in market factors

	December 31
	2023			2022
Gain (loss) from change:
5% increase in NIS and EURO exchange rate	$	176		$	257
5% decrease in NIS and EURO exchange rate	$	(176	)	$	(257	)

Schedule of liquidity risk by holding cash balances, short-term deposits and secured bank credit facilities

	December 31, 2023
	Carrying		12 months
	amount		or less		1-2 years		2-15 years
Non-derivative financial liabilities
Current liabilities
Current maturities of long-term liabilities		3,249		3,249		-		-
Trade payables and accrued expenses		5,528		5,528		-		-
Other payables		3,891		3,891		-		-
Non-current liabilities
Liabilities in respect of IIA grants		15,927		-		359		15,568
Liabilities in respect of TEVA		3,200		-		1,000		2,200
Lease liabilities		10,189		-		813		9,376

	December 31, 2022
	Carrying		12 months
	amount		or less		1-2 years		2-8 years
Non-derivative financial liabilities
Current liabilities
Current maturities of long-term liabilities		2,814		2,814		-		-
Trade payables and accrued expenses		5,656		5,656		-		-
Other payables		4,159		4,159		-		-
Non-current liabilities
Liabilities in respect of IIA grants		15,464		-		312		15,152
Liabilities in respect of TEVA		4,200		-		1,000		3,200
Lease liabilities		902		-		508		394

Share-Based Compensation (Schedule of Share Options Activity) (Details)	12 Months Ended
	Dec. 31, 2023 shares $ / shares	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
Number [Abstract]
Outstanding Options at beginning of year	764,767	537,288	513,973
Number of share options granted in share-based payment arrangement	346,950	320,775	53,970
Option's Exercised	0	(807)	(536)
Option's Forfeited and/or expired	(154,230)	(92,489)	(30,119)
Outstanding options and at end of year	957,487	764,767	537,288
Option's Exercisable at end of year	462,045	373,681	333,618
Weighted Average Exercise Price [Abstract]
Outstanding Options at beginning of year \| $ / shares	$ 30.44	$ 44.45	$ 45.85
Option's Granted \| $ / shares	11.87	14.25	37.52
Option's Exercised \| $ / shares	0	12.23	20.16
Option's Forfeited and/or expired \| $ / shares	57.55	55.58	56.91
Outstanding options and at end of year \| $ / shares	19.34	30.44	44.45
Option's Exercisable at end of year \| $ / shares	$ 26.25	$ 46.18	$ 58.38
Restricted Shares Units [Member]
Number [Abstract]
Outstanding Options at beginning of year	42,013	14,581	10,655
Number of share options granted in share-based payment arrangement	9,100	39,286	8,992
Option's Forfeited and/or expired	(941)	(27)	(215)
Option's Vested	(17,458)	(11,827)	(4,851)
Outstanding options and at end of year	32,714	42,013	14,581

Inventories (Schedule of inventories) (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Classes of current inventories [abstract]

Raw materials

$ 995

$ 913

Finished goods

1,851

^[1]

1,050

Inventories

2,846

$ 1,963

Inventory write-down

$ 326

[1]	Including write-down of $326

Share-Based Compensation (Narrative) (Details) $ / shares in Units, $ in Thousands				1 Months Ended					3 Months Ended	12 Months Ended
	Aug. 15, 2023 USD ($) shares	Apr. 03, 2023 USD ($) shares $ / shares	Mar. 04, 2021 USD ($) shares $ / shares	Nov. 20, 2023 USD ($) shares $ / shares	May 31, 2023 USD ($) shares	Feb. 15, 2023 USD ($) shares $ / shares	Aug. 18, 2022 USD ($) shares	Mar. 31, 2014	Jun. 30, 2022 USD ($) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Jun. 30, 2022 ₪ / shares	Jun. 30, 2022 $ / shares	Dec. 31, 2021 USD ($)
2014 Share Incentive Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement \| shares					1,000,000
Employees and directors [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares available for future grant \| shares										861,255
Fair value of options granted										$ 1,392	$ 2,970			$ 2,320
Employees and directors [Member] \| 2003 Israeli Share Option Plan ("Plan") [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercisable period										5-10 years
Description of vesting requirements for share-based payment arrangement										3-4 years
Employees and directors [Member] \| Restricted Shares Unit [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares available for future grant \| shares										990,201
Employees and directors [Member] \| Restricted Shares Unit [Member] \| 2014 Equity Incentive Plan (the "2014 Plan") [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercisable period								5-10 years
Description of vesting requirements for share-based payment arrangement								1-4 years
Employees and directors [Member] \| 2014 Share Incentive Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted, exercise price \| $ / shares			$ 37.52
Directors [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercisable period					five years
Description of vesting requirements for share-based payment arrangement	1 year			1-4 years		1-4 years
Number of other equity instruments granted in share-based payment arrangement \| shares									292,203
Options granted, exercise price \| $ / shares		$ 11.91		$ 8.13
Fair value of options									$ 2,314
Expense from share-based payment transitions					$ 146
Directors [Member] \| Restricted Shares Unit [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement \| shares									39,286
Options granted, exercise price \| $ / shares													$ 14.42
Fair value of options									$ 498
Directors [Member] \| 2014 Share Incentive Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement \| shares	7,200	160,400	34,013	48,750		130,600
Options granted, exercise price \| (per share)		$ 11.89		$ 8.78								₪ 9.63
Fair value of options	$ 42	$ 884	$ 663	$ 265
Directors [Member] \| 2014 Share Incentive Plan [Member] \| Restricted Shares Unit [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement \| shares			5,669			9,100
Fair value of options			$ 196
Employees [Member] \| 2014 Share Incentive Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement \| shares			19,958
Fair value of options			$ 417
Employees [Member] \| 2014 Share Incentive Plan [Member] \| Restricted Shares Unit [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement \| shares			3,324
Fair value of options			$ 116
Chairman [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement \| shares							28,572
Fair value of options							$ 284
Directors and CEO [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement \| shares									151,786
Fair value of options									$ 1,171
Directors and CEO [Member] \| Restricted Shares Unit [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in share-based payment arrangement \| shares									39,286
Fair value of options									$ 498
Employees, Officers, Board Members CEO and Consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement						1-4 years
Employees, Officers, Board Members CEO and Consultants [Member] \| 2014 Share Incentive Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted, exercise price \| $ / shares						$ 13.32
Fair value of options						$ 1,012
Employees, Officers, Board Members CEO and Consultants [Member] \| 2014 Share Incentive Plan [Member] \| Restricted Shares Unit [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value of options						$ 117

Short-term and restricted bank deposits (Schedule of short-term bank deposits) (Detail) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Disclosure Of Short Term Bank Deposits [Abstract]

Restricted bank deposits

$ 167

^[1]

$ 0

^[2]

USD bank deposits

^[3]

29,675

Short-term and restricted bank deposits

$ 29,842

$ 0

[1]	Restricted bank deposits which are primarily used as security for the Company’s office leases.
[2]	Restricted bank deposits which are primarily used as security for the Company’s office leases.
[3]	The USD deposits bear annual interest of 6.26%-6.55% for the period of 91-365 days for 2023.

Short-term and restricted bank deposits

12 Months Ended

Dec. 31, 2023

Disclosure Of Short Term Bank Deposits [Abstract]

Short-term and restricted bank deposits

Note 5:

Short-term and restricted bank deposits

	December 31
	2023		2022

Restricted bank deposits (1)		167		-
USD Bank deposits (2)		29,675		-

		29,842		-

(1)

Restricted bank deposits which are primarily used as security for the Company’s office leases.

(2)

The USD deposits bear annual interest of 6.26%-6.55% for the period of 91-365 days for 2023.

Cash And Cash Equivalents (Tables)

12 Months Ended

Dec. 31, 2023

Cash and cash equivalents [abstract]

Schedule of cash and cash equivalents

	December 31
	2023		2022

Balance in USD		4,151		24,475
Balance in other currencies		7,715		9,420

		11,866		33,895

Subsiquents events

12 Months Ended

Dec. 31, 2023

Disclosure of non-adjusting events after reporting period [abstract]

Subsequent events

Note 25:

Subsequent events:

On January 1, 2024, the company entered into a new lease agreement for 380.21 square meters of office, in Yavne, Israel, close to the main office, the agreement is for two years with options for additional three years. The additional leased area is needed to support the company in extending its activity. The annual fee for this agreement is ILS 437 (approximately $120).

On February 26, 2024, the Company granted to employees, officers, board members, CEO and some consultants 311,022 share options for an exercise price of $12.73 per share and 30,482 RSUs. The share options vest over a period of 1-4 years. The grant to the directors and CEO is subject to the approval of the next shareholders annual meeting.

On March 6, 2024, 37,106 warrants were exercised to the Company shares for exercise price of $13.475 per ordinary share, in accordance with the terms of the warrants (See also note 19 C.2).

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of terms and conditions of share-based payment arrangement [line items]

Schedule of expense recognized

	Year ended December 31
	2023		2022		2021
Cost of revenues		271		184		153
Research and development		485		406		333
Selling and marketing		87		42		-
General and administrative		1,097		1,314		1,187

Total share-based compensation		1,940		1,946		1,673

Schedule of share options activity

	2023					2022					2021
	Number of options			Weighted Average Exercise price		Number of options			Weighted Average Exercise price		Number of options			Weighted Average Exercise price

Outstanding Options at beginning of year		764,767			30.44		537,288			44.45		513,973			45.85
Options Granted		346,950			11.87		320,775			14.25		53,970			37.52
Options Exercised		-			-		(807	)		12.23		(536	)		20.16
Options Forfeited and/or expired		(154,230	)		57.55		(92,489	)		55.58		(30,119	)		56.91

Outstanding options at end of year		957,487			19.34		764,767			30.44		537,288			44.45

Option's Exercisable at end of year		462,045			26.25		373,681			46.18		333,618			58.38

Schedule of information about share options outstanding

	Options outstanding as of December 31, 2023
Range of exercise prices ($ )	Number of options		Weighted Average Remaining contractual life		Weighted average exercise price

8.26-9.64		55,950		9.85		8.44
11.89-14.42		711,124		7.89		13.20
26.88-37.52		125,535		5.62		35.99
42.14-67.06		64,878		1.85		63.84
Total		957,487		7.29		19.34

	Options outstanding as of December 31, 2022
Range of exercise prices ($ )	Number of options		Weighted Average Remaining contractual life		Weighted average exercise price

12.25-14.42		470,693		7.84		13.60
26.88-37.52		145,354		6.43		35.95
42.14-67.06		68,662		2.85		63.94
90.23-96.32		80,058		0.91		90.65
Total		764,767		6.40		30.44

Schedule of fair value assumptions

	December 31
	2023		2022		2021
Dividend yield (%)		0		0		0
Expected volatility of the share prices (%)		61-77		59-77		55-78
Risk‑free interest rate (%)		2.1-5.36		2.1-5.2		0.1-1.5
Early exercise factor (%)		100-150		100-150		100-150
Weighted average share prices (Dollar)		10.71		13.22		36.33

Restricted Shares Unit [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Schedule of share options activity

	RSU's 2023			RSU's 2022			RSU's 2021

Outstanding at beginning of year		42,013			14,581			10,655
Granted		9,100			39,286			8,992
Forfeited		(941	)		(27	)		(215	)
Vested		(17,458	)		(11,827	)		(4,851	)

Outstanding at the end of the period		32,714			42,013			14,581

Material Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of significant accounting policies [Abstract]

Schedule of depreciation on straight-line basis over useful life of assets

		%
Office furniture		7-10
Manufacturing machinery and lab equipment		15-33
Computers		33
Leasehold improvements		See below

Schedule of amortization periods of right-of-use assets

		Years
Motor vehicles		3
Buildings		6-15

Leases

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Leases

Note 11:

Leases

Lease Agreements:

The Company's offices and its production facility in Israel are located in a building that the Company leased from its Related party (see Note 24a), in accordance with a sub-lease agreement. The Company subleased approximately 3,000 square meters of laboratory, office and clean rooms space at a monthly rent fee NIS 125 (approximately $35). This sub-lease agreement was amended in October 2021, to extend the period up to October 2025 which was included in the calculation of the lease liability and RoU asset.

In July 2023, the company signed a termination agreement for the sub-lease agreement and signed on a new lease agreement for the same area of approximately 3,000 square meters in the same building with the owner of the building at a monthly rent fee of NIS 195 (approximately $54). The lease agreement is for 12 years with an option for an additional 3 years. The company estimation is to use the 3 years option

In addition, the Company and its subsidiary have lease agreements for 16 vehicles for the remaining period of 1.75 years on average.

Amounts recognized in profit or loss and in the statement of cash flows

	Year ended December 31,
	2023		2022

Interest expense on lease liabilities		274		102
Depreciation expenses		565		537
Cash outflow for leases		778		701

The Company determined the appropriate interest rate for discounting leases, with the assistance of a third party. The valuation was based on: credit risk, the weighted average term of the leases and other economic variables. A weighted average interest rate in a range of 1% to 8.47% was used to discount future lease payments in the calculation of the lease liability on the date of initial application of the standard (IFRS 16).

Disclosures in respect of Right- of- Use assets:

	Buildings			Motor vehicles			Total
Cost
Balance as of January 1, 2023		2,341			550			2,891
New leases		6,460			407			6,867
Adjustments for indexation		78			3			81
Disposals		(2,368	)		(308	)		(2,676	)

Balance as of December 31, 2023		6,511			652			7,163

Accumulated depreciation
Balance as of January 1, 2023		1,342			334			1,676
Depreciation and amortization		334			231			565
Capitalized to Leasehold improvements		59			-			59
Disposals		(1,527	)		(308	)		(1,835	)

Balance as of December 31, 2023		208			257			465

Depreciated cost
Balance as of December 31, 2023		6,303			395			6,698

	Buildings		Motor vehicles			Total
Cost
Balance as of January 1, 2022		2,267		654			2,921
New leases		-		125			125
Adjustments for indexation		74		9			83
Disposals		-		(238	)		(238	)

Balance as of December 31, 2022		2,341		550			2,891

Accumulated depreciation
Balance as of January 1, 2022		1,028		345			1,373
Depreciation and amortization		314		225			539
Disposals		-		(236	)		(236	)

Balance as of December 31, 2022		1,342		334			1,676

Depreciated cost
Balance as of December 31, 2022		999		216			1,215

Disclosures of the Company's lease liabilities:

	Buildings			Motor vehicles			Total

Balance as of January 1, 2023		1,199			179			1,378
Repayment of leases liabilities		(588	)		(190	)		(778	)
Effect of changes in exchange rates		(19	)		2			(17	)
New finance lease obligation recognized		6,460			365			6,825
Adjustments for indexation		78			3			81
Financial expenses		257			17			274
Disposals-Termination of leases		(1,041	)		(11	)		(1,052	)
Balance as of December 31, 2023		6,346			365			6,711

Current maturities of long-term leases		(180	)		(181	)		(361	)
Lease liability Balance as of December 31, 2023		6,166			184			6,350

	Buildings			Motor vehicles			Total

Balance as of January 1, 2022		1,691			299			1,990
Repayment of leases liabilities		(477	)		(224	)		(701	)
Effect of changes in exchange rates		(182	)		(28	)		(210	)
New finance lease obligation recognized		-			117			117
Adjustments for indexation		74			9			83
Financial expenses		93			8			101
Disposals-Termination of leases		-			(2	)		(2	)
Balance as of December 31, 2022		1,199			179			1,378

Current maturities of long-term leases		(399	)		(133	)		(532	)
Lease liability Balance as of December 31, 2022		800			46			846

Other Receivables- Long Term (Schedule of other receivables long term) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Trade and other non-current receivables [abstract]
Income receivables	$ 50	$ 180
Prepaid expenses	183	0
Other Receivables- Long Term	$ 233	$ 180

Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($)
$ in Thousands

Share capital [Member]

Share premium [Member]

Foreign currency translation reserve [Member]

Accumulated deficit [Member]

Total

Balance at Dec. 31, 2020

$ 75

$ 142,193

$ (40)

$ (134,956)

$ 7,272

Net loss

(13,551)

Other comprehensive Income

Total comprehensive loss

(13,551)

(13,530)

Exercise of options

^[1]

Share-based compensation

1,673

Balance at Dec. 31, 2021

143,869

(19)

(148,507)

(4,582)

Net loss

(19,599)

Other comprehensive Income

Total comprehensive loss

(19,599)

(19,585)

Exercise of pre-funded warrants

15,678

15,706

Exercise of options

^[1]

Issuance of ordinary shares, net of issuance expenses

17,389

17,429

Share-based compensation

1,946

Balance at Dec. 31, 2022

143

178,882

(5)

(168,106)

10,914

Net loss

(6,716)

Other comprehensive Income

(13)

Total comprehensive loss

(13)

(6,716)

(6,729)

Exercise of RSU

Issuance of ordinary shares, net of issuance expenses

25,429

25,469

Share-based compensation

1,940

Balance at Dec. 31, 2023

$ 184

$ 206,251

$ (18)

$ (174,822)

$ 31,595

[1]	Represents an amount lower than $1.

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2023-01-01
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2023-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2023-01-01
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2023-03-23

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2023-03-23

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard
-URIDate 2023-03-23

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 17
-IssueDate 2023-01-01
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2023-03-23

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2023-03-23

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2023-03-23

+ Details

Other Receivables Short Term (Schedule of other receivables short term) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Trade and other current receivables [abstract]
Government authorities	$ 322	$ 193
Income receivables	397	170
Prepaid expenses and other	722	287
Other Receivables- Short Term	$ 1,441	$ 650

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss (Schedule of Research Expenses) (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Disclosure of transactions between related parties [abstract]

Salary and benefits (including share-based compensation)

^[1]

$ 3,148

$ 4,494

$ 2,864

Subcontractors

2,833

4,054

6,323

Depreciation and amortization

396

571

396

Cost of materials

785

572

347

Other research and development expenses

305

490

326

Total Research and development

$ 7,467

$ 10,181

$ 10,256

[1]	The salary costs for the year ended December 31,2022 includes one time payment of $205 derived from termination agreement with the CMO of the company.

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about intangible assets [abstract]

Schedule of intangible assets

	License and Knowhow
	2023		2022
Cost
Balance as of January 1,		1,538		1,538
Additions		-		-
Balance as of December 31,		1,538		1,538
Accumulated Amortization
Balance as of January 1,		1,307		1,241
Additions		66		66
Balance as of December 31,		1,373		1,307
Amortized cost
Balance as of December 31,		165		231

Balances and Transactions With Related Parties and Key Officers

12 Months Ended

Dec. 31, 2023

Disclosure of transactions between related parties [abstract]

Balances And Transactions With Related Parties And Key Officers

Note 24:

Balances and Transactions with Related Parties and Key Officers

Related parties consist of:

•

Clal Biotechnologies Industries Ltd.- Related party (see also note 11)

•

Directors of the Company.

Balances with related parties:

	Other Payables
Related Party:
As of December 31, 2023		-
As of December 31, 2022		177

Directors:
As of December 31, 2023		83
As of December 31, 2022		130

Transactions with related parties:

Rental fee:

	Year ended December 31
	2023		2022		2021
Related party		267		457		469

Professional fee *:

	Year ended December 31
	2023		2022		2021

Directors		502		484		375
Related party		25		63		85
		527		547		460
Number of Directors		***9		**10		8

Not included share- based compensation detailed in Note 20.

During 2022 two members of the board of directors were replaced.

***

During 2023 three members of the board have left and one member of the board was replaced. At the end of 2023, the total board member consisted of five members.

b. Key Officers:

Balances with Key Officers of the Company

	*Other* *Payables*
Key Officers of the Company

As of December 31, 2023		518
As of December 31, 2022		754

•

Represents the officer’s gross salary, bonuses, and vacation provisions without share based compensation.

Compensation of Key Officers of the Company:

The following amounts disclosed in the table are recognized as an expense during the reporting period related to officers:

	Year ended December 31
	2023		2022	2021
Short-term employee benefits ()(*)		2,084	2,880	1,788
Share-based compensation		757	797	518

		2,841	3,677	2,306
Number of officers (***)		8	7	5

(*) One-time expenses amounted $309 for the year ended December 31, 2022, are associated with the management changes.

(**) In December 2007, the Company's board of directors approved one‑time bonus payments to the Chief Medical Officer in the amounts of $ 120, which was recorded in profit and loss in December 2022 upon achieving marketing approval in the United States.

(***) During 2023 two key officers were replaced. At the end of 2023 the total key officers consist of six officers.

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss

12 Months Ended

Dec. 31, 2023

Disclosure of supplementary information to the statements of profit and lost and other comprehensive loss [Abstract]

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss

Note 22:

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss

Additional information on Revenues:

Major customers:

BARDA contributed 56%, 51% and 76% of the Company’s total revenues in 2023, 2022 and 2021 respectively. Vericel contributed 4% and 28% of the Company’s total revenues in 2023 and 2022 respectively. MTEC contributed 10% and 2.8% of the Company’s total revenues in 2023 and 2022 respectively (see also Note 18).

No other customer contributed 10% or more of the Company’s revenues in 2023, 2022 and 2021.

Geographic information:

The revenues reported in the financial statements are based on the location of the customers, as follows:

	Year ended December 31
	2023		2022		2021

USA (see also Note 18a, 18b, 18c)		13,078		21,872		18,102
EU and other international markets		5,608		4,624		5,661

		18,686		26,496		23,763

Cost of Revenues:

Cost of Revenues from sale of products

	Year ended December 31
	2023			2022			2021

Salary and benefits (including share-based compensation)		2,703			1,828			2,047
Subcontractors		230			58			190
Depreciation and amortization		672			426			559
Cost of materials		916			636			1,039
Other manufacturing expenses		1,207			779			906
Decrease (increase) in inventory of finished products		(801	)		(543	)		242

		4,927			3,184			4,983

Cost of Revenues from development services

	Year ended December 31
	2023		2022		2021

Salary and benefits		1,995		1,691		2,003
Subcontractors		8,182		8,138		7,904

		10,177		9,829		9,907

Cost of Revenues from license agreements

	Year ended December 31
	2023		2022		2021

Salary and benefits		4		38		102
Royalties payments		-		280		-

		4		318		102

Total Cost of Revenues		15,108		13,331		14,992

Research and development expenses:

	Year ended December 31
	2023		2022		2021

Salary and benefits (including share-based compensation) (1)		3,148		4,494		2,864
Subcontractors		2,833		4,054		6,323
Depreciation and amortization		396		571		396
Cost of materials		785		572		347
Other research and development expenses		305		490		326

Total Research and development		7,467		10,181		10,256

(1)

The salary costs for the year ended December 31,2022 includes one-time payment of $205 derived from termination agreement with the CMO of the company.

Selling and marketing expenses:

	Year ended December 31
	2023		2022		2021

Salary and benefits (including share-based compensation)		1,991		1,637		1,643
Marketing and consulting		1,637		1,152		627
Depreciation and amortization		50		49		44
Shipping and delivery		356		385		490
Registration and marketing license fees		810		502		584

		4,844		3,725		3,388

General and administrative expenses:

	Year ended December 31
	2023		2022		2021
Salary and benefits (including share‑based compensation)		3,521		3,344		2,905
Professional fees		2,189		2,589		2,480
Depreciation and amortization		185		225		239
Other		873		762		724

		6,768		6,920		6,348

Other (income) expenses:

The other one-time income amounted $211 for the year ended December 31, 2023, is associated with the termination of sub-lease agreement (see note 11a).

The other one-time expenses amounted $684 for the year ended December 31, 2022, are associated with the management changes and FDA milestone payment fee (see Note 18b).

Financial income and expense:

	Year ended December 31
	2023		2022			2021
Financial income:

Interest income		2,341		270			11
Revaluation of liabilities in respect of IIA grants		-		132			-
Revaluation of Warrants		8,310		-			-
Exchange differences, net		-		59			-

		10,651		461			11
Financial expense:

Revaluation of liabilities in respect of IIA grants		427		-			903
Financing income on net investment in lease		274		102			120
Finance expenses in respect of deferred revenues		8		54			143
Revaluation of liabilities in respect of TEVA		468		533			590
Exchange differences, net		654		-			511
Revaluation of Warrants		-		8,977			-
Issuance expenses of warrants through profit and loss		-		1,911			-
Other		61		60			47

		1,892		11,637			2,314

Financial income (expenses), net		8,759		(11,176	)		(2,303	)

Basis of Preparation of the Consolidated Financial Statements

12 Months Ended

Dec. 31, 2023

Disclosure Of Basis Of Preparation Of Consolidated Financial Statements [Abstract]

Basis of Preparation of the Consolidated Financial Statements

Note 2:

Basis of Preparation of the Consolidated Financial Statements

Statement of compliance with International Financial Reporting Standards

These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

These consolidated financial statements were approved by the board of directors on March 21, 2024.

Functional currency, reporting currency and foreign currency:

Functional currency and reporting currency:

The reporting currency of the financial statements is the U.S. dollar.

The Company determines the functional currency based on the currency in which it primarily generates and expends cash. The Company determined that its functional currency is the U.S. dollar since most of the Company's revenues are in U.S. dollars and the economic environment in which the Company operates in and performs its transactions is mostly affected by the U.S dollar. A certain portion of the Company's costs are denominated in NIS mainly due to payroll and related benefit costs incurred in Israel. To further support the Company's determination, the Company has analyzed the currency in which funds from financing activities are generated or held and the currency in which receipts from operating activities are usually retained. In this respect, funds from financing activities were principally derived from significant funds raising in U.S. dollars and U.S governmental funds.

The Company operates and plans its activities in U.S. dollars and accordingly its periodic budgets and internal management reports are prepared and monitored using the U.S. dollar as the primary currency and provides the basis for the determination of share-based compensation.

The functional currency of the Company's subsidiary in Germany has been determined to be its local currency - the EURO. Assets and liabilities of this subsidiary are translated at year end exchange rates and its statement of operations items are translated using the average exchange rates at the quarter of which those items are recognized. Such translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss) in shareholders' equity (deficit).

Transactions, assets and liabilities in foreign currency:

Transactions denominated in foreign currency are recorded upon initial recognition at the exchange rate on the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date.

Exchange differences are recognized in profit or loss.

Use of estimates and judgments

The preparation of financial statements in conformity with IFRSs requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Discussed below are the key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

•

Determining the fair value of share-based compensation to employees and directors:

The fair value of share-based compensation to employees and directors is determined using the binomial option pricing models. The assumptions used in the models include the expected volatility, early exercise factor, expected dividend and risk-free interest rate.

•

Liabilities in respect to IIA grants:

Government grants received from the IIA are recognized as a liability if future economic benefits are expected from the research and development activity that will result in royalty‑bearing sales. As the contingent liability is calculated based on future royalty-bearing sales, there is uncertainty regarding the estimated future cash flows and the estimated discount rate used to measure the amortized cost of the liability.

•

Fair value estimations of warrants

The Company completed financing transactions in which it issued shares and warrants to purchase additional shares. The fair value of the warrants, which are not traded on an active market, is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity specific estimates.

Property, Plant And Equipment, Net (Schedule of property, plant and equipment, net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Balance	$ 2,366
Balance	9,228	$ 2,366
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	8,829	8,334
Additions	7,475	555
Disposals		(59)
Capitalization of depreciation of ROU assets	59
Foreign currency translation	1	(1)
Balance	16,364	8,829
Cost [Member] \| Office furniture [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	293	257
Additions	25	37
Disposals		0
Capitalization of depreciation of ROU assets	0
Foreign currency translation	1	(1)
Balance	319	293
Cost [Member] \| Manufacturing machinery and lab equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	5,091	4,764
Additions	7,312	327
Disposals		0
Capitalization of depreciation of ROU assets	0
Foreign currency translation	0	0
Balance	12,403	5,091
Cost [Member] \| Computers [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	166	176
Additions	101	49
Disposals		(59)
Capitalization of depreciation of ROU assets	0
Foreign currency translation	0	0
Balance	267	166
Cost [Member] \| Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	3,279	3,137
Additions	37	142
Disposals		0
Capitalization of depreciation of ROU assets	59
Foreign currency translation	0	0
Balance	3,375	3,279
Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(6,463)	(5,856)
Additions	672	667
Disposals		59
Foreign currency translation	1	(1)
Balance	(7,136)	(6,463)
Accumulated Depreciation [Member] \| Office furniture [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(157)	(133)
Additions	26	25
Disposals		0
Foreign currency translation	1	(1)
Balance	(184)	(157)
Accumulated Depreciation [Member] \| Manufacturing machinery and lab equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(3,818)	(3,370)
Additions	448	448
Disposals		0
Foreign currency translation	0	0
Balance	(4,266)	(3,818)
Accumulated Depreciation [Member] \| Computers [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(97)	(94)
Additions	58	62
Disposals		59
Foreign currency translation	0	0
Balance	(155)	(97)
Accumulated Depreciation [Member] \| Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(2,391)	(2,259)
Additions	140	132
Disposals		0
Foreign currency translation	0	0
Balance	(2,531)	(2,391)
Depreciated cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	2,366
Balance	9,228	2,366
Depreciated cost [Member] \| Office furniture [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	136
Balance	135	136
Depreciated cost [Member] \| Manufacturing machinery and lab equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	1,273
Balance	8,137	1,273
Depreciated cost [Member] \| Computers [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	69
Balance	112	69
Depreciated cost [Member] \| Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	888
Balance	$ 844	$ 888

Net Loss Per Share

12 Months Ended

Dec. 31, 2023

Earnings per share [abstract]

Net Loss Per Share

Note 23:

Net Loss Per Share

Details of the number of shares and loss used in the computation of loss per share:

Year ended December 31
2023					2022					2021
Weighted average number of shares		Loss			Weighted average number of shares		Loss			Weighted average number of shares		Loss

	9,013,144		(6,716	)		4,987,069		(19,599	)		3,892,068		(13,551	)

Net loss per share:

	Year ended December 31
	2023			2022			2021

Basic and diluted loss per share:		(0.75	)		(3.93	)		(3.48	)

In 2023, 2,614,297 warrants, 957,487 options and 32,714 RSU’s were excluded from the diluted weighted average number of Ordinary Shares calculation as their effect would have been anti-dilutive.

In 2022, 2,614,297 warrants, 764,767 options and 42,013 RSU’s were excluded from the diluted weighted average number of Ordinary Shares calculation as their effect would have been anti-dilutive. In addition, the impact of 1,407,583 pre-funded warrants which were exercised in December 2022, have not taken in the diluted weighted average number of Ordinary Shares calculation as their effect would have been anti-dilutive as well.

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss (Schedule of Cost of Revenue License) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of comprehensive income [abstract]
Salary and benefits	$ 4	$ 38	$ 102
Royalties payments	0	280	0
Total Royalties payments	4	318	102
Total Cost of Revenues	$ 15,108	$ 13,331	$ 14,992

Financial Instruments

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about financial instruments [abstract]

Financial Instruments

Note 15:

Financial Instruments

Risk management:

The Board of Directors has overall responsibility for the establishment and oversight of the Company’s risk management framework.

The Company’s risk management practice was formulated to identify and analyze the risks that the Company faces, to set appropriate limits for the risks and controls, and to monitor the risks and their compliance within the limits. The risk policy and risk management methods are reviewed regularly to reflect changes in market conditions and in the Company’s operations.

The Company Audit Committee oversees how management monitors compliance with the Company’s risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The Company Audit Committee is assisted in its oversight role by Internal Audit. Internal Audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the Audit Committee.

The Company's activities expose it to various financial market risks, mainly foreign currency risk, interest rate risk and liquidity risk.

Foreign currency risk

The Company operates primarily in an international environment and is exposed to foreign exchange risk resulting from the fact that a certain portion of the Company's costs are denominated in NIS and EURO, mainly due to payroll and related benefit costs incurred in Israel and additionally due to marketing expenses incurred in Europe.

Sensitivity tests relating to changes in market factors:

The Company operates in an international environment and is exposed to foreign exchange risk resulting from the exposure to different currencies, mainly NIS and EURO. Foreign exchange risks arise from recognized assets and liabilities denominated in a foreign currency other than the functional currency.

	December 31
	2023			2022
Gain (loss) from change:
5% increase in NIS and EURO exchange rate	$	176		$	257
5% decrease in NIS and EURO exchange rate	$	(176	)	$	(257	)

The Company has performed sensitivity tests of principal market risk factors that may affect its reported operating results or financial position.

The sensitivity tests present the profit or loss for the relevant risk variables chosen as of each reporting date.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to timely meet its liabilities, under both normal and stressed conditions, without incurring unwanted losses.

The Company manages the liquidity risk by holding cash balances, short-term deposits and secured bank credit facilities.

	December 31, 2023
	Carrying		12 months
	amount		or less		1-2 years		2-15 years
Non-derivative financial liabilities
Current liabilities
Current maturities of long-term liabilities		3,249		3,249		-		-
Trade payables and accrued expenses		5,528		5,528		-		-
Other payables		3,891		3,891		-		-
Non-current liabilities
Liabilities in respect of IIA grants		15,927		-		359		15,568
Liabilities in respect of TEVA		3,200		-		1,000		2,200
Lease liabilities		10,189		-		813		9,376

	December 31, 2022
	Carrying		12 months
	amount		or less		1-2 years		2-8 years
Non-derivative financial liabilities
Current liabilities
Current maturities of long-term liabilities		2,814		2,814		-		-
Trade payables and accrued expenses		5,656		5,656		-		-
Other payables		4,159		4,159		-		-
Non-current liabilities
Liabilities in respect of IIA grants		15,464		-		312		15,152
Liabilities in respect of TEVA		4,200		-		1,000		3,200
Lease liabilities		902		-		508		394

Fair value:

(1)

Financial instruments measured at fair value for disclosure purposes only.

The carrying amounts of certain financial assets and liabilities, including cash, trade receivables, other receivables, deposits, trade and other payables are the same as or approximate to their fair value.

(2)

Fair value hierarchy of financial instruments measured at fair value.

The financial instruments measured at fair value on a temporal basis, use valuation methodology in accordance with the fair value hierarchy levels when determining the fair value of an asset or liability, the Company uses observable market data as much as possible.

Details regarding fair value measurement at Level 2

The fair value of the warrants which are classified as non-currents liabilities was measured by using Black and Scholes model. The following inputs were used to determine the fair value:

Expected period of warrants– 2.91 years.

Expected volatility – 67.1%

Risk-free interest rate (3) – 4.03%

Expected dividend yield – 0%.

The fair value of liabilities in respect to IIA grants with fixed interest is based on a calculation of the present value of the cash flows at the interest rate for a loan with similar terms. The Company used a discount rate of 12% based in part of the Company’s estimation at the time of the Company’s recognition of the IIA grants which approximates the fair value at the respective balance sheet date.

The liability in respect of TEVA as presented in balance sheet which is approximate its fair value, based on a calculation of the present value of future payments. The expected cash flows already reflect assumptions about the uncertainty in future defaults, and therefore the Company used a discount rate of 14% that is commensurate with the risk inherent in the expected cash flows (Note 17c).

Liabilities in Respect of IIA Grants

12 Months Ended

Dec. 31, 2023

Disclosure of israeli innovation authority grants [Abstract]

Liabilities in Respect of IIA Grants

Note 14:

Liabilities in Respect of IIA Grants

	December 31
	2023			2022

Balance as of January 1,		7,566			8,105
Royalties		(190	)		(407	)
Amounts carried to Profit or Loss		427			(132	)
Balance as of December 31,		7,803			7,566

Current maturities		(126	)		(121	)
Long term liabilities in respect of IIA grants		7,677			7,445

The Company is committed to pay royalties to the IIA up to the total grants received plus the applicable accrued interest. The total amount of grants received from IIA including accrued interest, net of royalties as of December 31, 2023 is approximately $13,783, while the amortized cost of this liability as of that date is $ 7,803, using the interest method.

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss (Schedule of Selling Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [abstract]
Salary and benefits (including share-based compensation)	$ 1,991	$ 1,637	$ 1,643
Marketing and consulting	1,637	1,152	627
Depreciation and amortization	50	49	44
Shipping and delivery	356	385	490
Registration and marketing license fees	810	502	584
Selling and marketing	$ 4,844	$ 3,725	$ 3,388

Financial Instruments (Schedule of liquidity risk by holding cash balances, short-term deposits and secured bank credit facilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Non-current liabilities
Lease liabilities	$ 6,350	$ 846
Carrying amount [Member]
Current liabilities
Current maturities of long-term liabilities	3,249	2,814
Trade payables and accrued expenses	5,528	5,656
Other payables	3,891	4,159
Non-current liabilities
Liabilities in respect of IIA grants	15,927	15,464
Liabilities in respect of TEVA	3,200	4,200
Lease liabilities	10,189	902
12 months or less [Member]
Current liabilities
Current maturities of long-term liabilities	3,249	2,814
Trade payables and accrued expenses	5,528	5,656
Other payables	3,891	4,159
Non-current liabilities
Liabilities in respect of IIA grants	0	0
Liabilities in respect of TEVA	0	0
Lease liabilities	0	0
1-2 years [Member]
Current liabilities
Current maturities of long-term liabilities	0	0
Trade payables and accrued expenses	0	0
Other payables	0	0
Non-current liabilities
Liabilities in respect of IIA grants	359	312
Liabilities in respect of TEVA	1,000	1,000
Lease liabilities	813	508
2-15 years [Member]
Current liabilities
Current maturities of long-term liabilities	0	0
Trade payables and accrued expenses	0	0
Other payables	0	0
Non-current liabilities
Liabilities in respect of IIA grants	15,568	15,152
Liabilities in respect of TEVA	2,200	3,200
Lease liabilities	$ 9,376	$ 394

Financial Instruments (Narrative) (Details)	12 Months Ended
Financial Instruments (Narrative) (Details)	Dec. 31, 2023
Fair value measurement at Level 3 [Member]
Disclosure of detailed information about financial instruments [line items]
Expected period of warrants	2 years 10 months 28 days
Expected volatility, warrants	67.10%
Expected dividend yield, warrants	0.00%
Fair value measurement at Level 3 [Member] \| Bottom of range [Member]
Disclosure of detailed information about financial instruments [line items]
Risk-free interest rate, warrants	4.03%
Interest rate for a loan [Member]
Disclosure of detailed information about financial instruments [line items]
Discount rate	12.00%
Uncertainty in future defaults [Member]
Disclosure of detailed information about financial instruments [line items]
Discount rate	14.00%

Equity (Schedule of Share Capital) (Details) - shares	Dec. 31, 2023	May 31, 2023	Feb. 07, 2023	Dec. 31, 2022	Dec. 05, 2022	Nov. 27, 2022
Disclosure of classes of share capital [abstract]
Authorized number of shares	20,000,000	1,400,000		12,857,143	90,000,000	50,000,000
Issued and outstanding number of shares	9,221,764		1,964,286	7,240,020

Liabilities in Respect of IIA Grants (Narrative) (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Disclosure of israeli innovation authority grants [Abstract]
Grants received net of royalties	$ 13,783
Amortized cost of grants received	$ 7,803

Net Loss Per Share (Schedule of Net Loss Per Share from Continuing and Discontinued Operations) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [abstract]
Basic and diluted loss per share:	$ (0.75)	$ (3.93)	$ (3.48)

Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2023 shares
Entity Addresses [Line Items]
Entity Registrant Name	MEDIWOUND LTD.
Entity Central Index Key	0001593984
Document Type	20-F
Document Period End Date	Dec. 31, 2023
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Emerging Growth Company	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity Common Stock, Shares Outstanding	9,221,764
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	IL
Entity File Number	001-36349
Entity Address, Address Line One	42 Hayarkon Street
Entity Address, City or Town	Yavne
Entity Address, Postal Zip Code	8122745
Entity Address, Country	IL
Title of 12(b) Security	Ordinary shares, par value NIS 0.07 per share
Trading Symbol	MDWD
Security Exchange Name	NASDAQ
Document Accounting Standard	International Financial Reporting Standards
Document Registration Statement	false
Auditor Firm ID	1057
Auditor Location	Haifa, Israel
Auditor Name	Somekh Chaikin
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	42 Hayarkon Street
Entity Address, City or Town	Yavne
Entity Address, Postal Zip Code	8122745
Entity Address, Country	IL
Contact Personnel Name	Yaron Meyer
City Area Code	972
Local Phone Number	971-4100
Contact Personnel Email Address	yaronm@mediwound.com

Other Receivables- Long Term (Tables)

12 Months Ended

Dec. 31, 2023

Trade and other non-current receivables [abstract]

Schedule of other long term receivables

	December 31,
	2023		2022

Income receivables		50		180
Prepaid expenses		183		-

		233		180

Consolidated Statements of Financial Position (Parenthetical)	Dec. 31, 2023 ₪ / shares shares	Dec. 31, 2022 ₪ / shares shares
Statement of financial position [abstract]
Par value per share \| (per share)	₪ 0.07	₪ 0.07
Number of shares authorised	20,000,000	12,857,143
Number of shares issued	9,221,764	7,240,020
Ordinary shares, Outstanding	9,221,764	7,240,020

Liabilities in Respect of IIA Grants (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of israeli innovation authority grants [Abstract]

Schedule of Israeli innovation authority grants

	December 31
	2023			2022

Balance as of January 1,		7,566			8,105
Royalties		(190	)		(407	)
Amounts carried to Profit or Loss		427			(132	)
Balance as of December 31,		7,803			7,566

Current maturities		(126	)		(121	)
Long term liabilities in respect of IIA grants		7,677			7,445

Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [abstract]
Revenues from sale of products	$ 6,261	$ 5,347	$ 9,613
Revenues from development services	12,265	12,943	12,372
Revenues from license agreements and royalties	160	8,206	1,778
Total revenues	18,686	26,496	23,763
Cost of revenues from sale of products	4,927	3,184	4,983
Cost of revenues from development services	10,177	9,829	9,907
Cost of revenues from license agreements	4	318	102
Total cost of revenues	15,108	13,331	14,992
Gross profit	3,578	13,165	8,771
Research and development	7,467	10,181	10,256
Selling and marketing	4,844	3,725	3,388
General and administrative	6,768	6,920	6,348
Other (income) expenses	(211)	684	0
Total operating expenses	18,868	21,510	19,992
Operating loss	(15,290)	(8,345)	(11,221)
Financial income	10,651	461	11
Financial expense	(1,892)	(11,637)	(2,314)
Financing income (expenses), net	8,759	(11,176)	(2,303)
Loss before taxes on income	(6,531)	(19,521)	(13,524)
Taxes on income	(185)	(78)	(27)
Net loss	(6,716)	(19,599)	(13,551)
Other comprehensive income (loss):
Foreign currency translation adjustments	(13)	14	21
Total comprehensive loss	$ (6,729)	$ (19,585)	$ (13,530)
Loss per share data:
Basic net loss per share - USD	$ (0.75)	$ (3.93)	$ (3.48)
Diluted net loss per share - USD	$ (0.75)	$ (3.93)	$ (3.48)
Number of shares used in calculating basic loss per share	9,013,144	4,987,069	3,892,068
Number of shares used in calculating diluted loss per share	9,013,144	4,987,069	3,892,068

Severance Pay Liability, Net (Details)	12 Months Ended
Severance Pay Liability, Net (Details)	Dec. 31, 2023
Disclosure of defined benefit plans [abstract]
Percentage of monthly deposit by employee	8.33%

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
One-time expenses		$ 684
One-time income	$ 211	$ 0	$ 0
BARDA [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Concentration Risk Percentage	56.00%	51.00%	76.00%
Vericel [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Concentration Risk Percentage	4.00%	28.00%
MTEC [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Concentration Risk Percentage	10.00%	2.80%
Other Customer Contributed [Member]
Disclosure of detailed information about property, plant and equipment [line items]
One-time expenses		$ 205

Balances and Transactions With Related Parties and Key Officers (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of transactions between related parties [abstract]

Schedule of balances of related parties

	Other Payables
Related Party:
As of December 31, 2023		-
As of December 31, 2022		177

Directors:
As of December 31, 2023		83
As of December 31, 2022		130

Schedule of transactions with related parties

Transactions with related parties:

Rental fee:

	Year ended December 31
	2023		2022		2021
Related party		267		457		469

Professional fee *:

	Year ended December 31
	2023		2022		2021

Directors		502		484		375
Related party		25		63		85
		527		547		460
Number of Directors		***9		**10		8

Not included share- based compensation detailed in Note 20.

During 2022 two members of the board of directors were replaced.

***

During 2023 three members of the board have left and one member of the board was replaced. At the end of 2023, the total board member consisted of five members.

Schedule of balances of key officers

	*Other* *Payables*
Key Officers of the Company

As of December 31, 2023		518
As of December 31, 2022		754

Schedule of compensation of officers of company

	Year ended December 31
	2023		2022	2021
Short-term employee benefits ()(*)		2,084	2,880	1,788
Share-based compensation		757	797	518

		2,841	3,677	2,306
Number of officers (***)		8	7	5

(*) One-time expenses amounted $309 for the year ended December 31, 2022, are associated with the management changes.

(***) During 2023 two key officers were replaced. At the end of 2023 the total key officers consist of six officers.

Financial Instruments (Schedule of sensitivity tests relating to changes in market factors) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Sensitivity Test To Changes In Nis And Euro Exchange Rates [Abstract]
Gain (loss) from change in exchange rate	$ (189)	$ (525)	$ 137
5% increase in NIS and EURO exchange rate [Member]
Sensitivity Test To Changes In Nis And Euro Exchange Rates [Abstract]
Gain (loss) from change in exchange rate	176	257
5% decrease in NIS and EURO exchange rate [Member]
Sensitivity Test To Changes In Nis And Euro Exchange Rates [Abstract]
Gain (loss) from change in exchange rate	$ (176)	$ (257)

Trade Receivables

12 Months Ended

Dec. 31, 2023

Trade and other current receivables [abstract]

Trade Receivables

Note 6:

Trade Receivables

	December 31
	2023			2022

Vericel (Note 18b)		236			7,500
BARDA (Note 18a)		1,245			701
MTEC (Note 18c)		617			362
Other trade receivables		1,608			771
Less provision for impairment		(6	)		(2	)

		3,700			9,332

Balances and Transactions With Related Parties and Key Officers (Schedule of Balances of Key Officers of the Company) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [line items]
Professional fee	$ 2,189	$ 2,589	$ 2,480
Key Officer [Member]
Disclosure of transactions between related parties [line items]
Professional fee	$ 518	$ 754

Material Accounting Policies (Schedule of depreciation on straight line basis over useful life of assets) (Details)

12 Months Ended

Dec. 31, 2023

Office furniture [Member]

Disclosure of detailed information about property, plant and equipment [line items]

Useful life of assets at annual rates (in %)

7-10

Manufacturing machinery and lab equipment [Member]

Disclosure of detailed information about property, plant and equipment [line items]

Useful life of assets at annual rates (in %)

15-33

Computers [Member]

Disclosure of detailed information about property, plant and equipment [line items]

Useful life of assets at annual rates (in %)

Leasehold improvements [Member]

Disclosure of detailed information about property, plant and equipment [line items]

Useful life of assets at annual rates (in %)

See below

^[1]

[1]	Leasehold improvements are depreciated on a straight‑line basis over the shorter of the lease term (including the renewal option held by the Company which is expected to be exercised) and the expected life of the improvement.

Intangible Assets, Net (Schedule of intangible assets, net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about intangible assets [line items]
Balance, opening	$ 231
Balance, ending	165	$ 231
Cost [Member] \| License and Knowhow [Member]
Disclosure of detailed information about intangible assets [line items]
Balance, opening	1,538	1,538
Additions	0	0
Balance, ending	1,538	1,538
Accumulated Amortization [Member] \| License and Knowhow [Member]
Disclosure of detailed information about intangible assets [line items]
Balance, opening	(1,307)	(1,241)
Additions	66	66
Balance, ending	(1,373)	(1,307)
Amortized cost [Member] \| License and Knowhow [Member]
Disclosure of detailed information about intangible assets [line items]
Balance, opening	231
Balance, ending	$ 165	$ 231

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	$ 18,686	$ 26,496	$ 23,763
USA [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	13,078	21,872	18,102
EU and other international markets [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	$ 5,608	$ 4,624	$ 5,661

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 28
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 23
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 32
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard
-URIDate 2023-03-23

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2023-03-23

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2023-03-23

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 34
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard
-URIDate 2023-03-23

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 82
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2023-03-23

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard
-URIDate 2023-03-23

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 102
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard
-URIDate 2023-03-23

+ Details

Property, Plant And Equipment, Net

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about property, plant and equipment [abstract]

Property, Plant And Equipment, Net

Note 10:

Property, Plant and Equipment, Net

	Office furniture			Manufacturing machinery and lab equipment		Computers			Leasehold improvements		Total
Cost

Balance as of January 1, 2023		293			5,091		166			3,279		8,829
Additions		25			7,312		101			37		7,475
Capitalization of depreciation of ROU assets		-			-		-			59		59
Foreign currency translation		1			-		-			-		1

Balance as of December 31, 2023		319			12,403		267			3,375		16,364

Balance as of January 1, 2022		257			4,764		176			3,137		8,334
Additions		37			327		49			142		555
Disposals		-			-		(59	)		-		(59	)
Foreign currency translation		(1	)		-		-			-		(1	)

Balance as of December 31, 2022		293			5,091		166			3,279		8,829

Accumulated Depreciation

Balance as of January 1, 2023		157			3,818		97			2,391		6,463
Additions		26			448		58			140		672
Foreign currency translation		1			-		-			-		1

Balance as of December 31, 2023		184			4,266		155			2,531		7,136

Balance as of January 1, 2022		133			3,370		94			2,259		5,856
Additions		25			448		62			132		667
Disposals		-			-		(59	)		-		(59	)
Foreign currency translation		(1	)		-		-			-		(1	)

Balance as of December 31, 2022		157			3,818		97			2,391		6,463

Carrying amounts of all fixed asset items
December 31, 2023		135			8,137		112			844		9,228
December 31, 2022		136			1,273		69			888		2,366

Trade Receivables (Schedule of trade receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Trade and other current receivables [abstract]
Vericel (Note 18b)	$ 236	$ 7,500
BARDA (Note 18a)	1,245	701
MTEC (Note 18c)	617	362
Other trade receivables	1,608	771
Less provision for impairment	(6)	(2)
Trade Receivables	$ 3,700	$ 9,332

Leases (Narrative) (Details)	1 Months Ended		12 Months Ended
Leases (Narrative) (Details)	Jul. 31, 2023 ILS (₪) ft² Vehicles	Jul. 31, 2023 USD ($) ft² Vehicles	Dec. 31, 2023 ILS (₪) ft²	Dec. 31, 2023 USD ($) ft²
Disclosure Of Finance Lease And Operating Lease By Lessee [Line Items]
Subsidiaries lease, area \| ft²	3,000	3,000	3,000	3,000
Subsidiaries lease, monthly rent				$ 35,000
Subsidiaries lease, expiration period	12 years	12 years
Subsidiaries lease, extention period	3 years	3 years
Subsidiaries lease, extented useful life	3 years	3 years
Number of vehicles in operating lease arrangements \| Vehicles	16	16
Period of vehicles operating lease arrangements	1.75 years	1.75 years
Re-classified to leasehold improvements				$ 59,000
Minimum [Member]
Disclosure Of Finance Lease And Operating Lease By Lessee [Line Items]
Weighted average incremental borrowing			1.00%	1.00%
Maximum [Member]
Disclosure Of Finance Lease And Operating Lease By Lessee [Line Items]
Weighted average incremental borrowing			8.47%	8.47%
NIS [Member]
Disclosure Of Finance Lease And Operating Lease By Lessee [Line Items]
Subsidiaries lease, monthly rent	₪ 195	$ 54	₪ 125

Share-Based Compensation

12 Months Ended

Dec. 31, 2023

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Share Based Compensation

Note 20:

Share‑Based Compensation

Expense recognized in the financial statements:

The expenses recognized for services received from employees and directors is as follows:

	Year ended December 31
	2023		2022		2021
Cost of revenues		271		184		153
Research and development		485		406		333
Selling and marketing		87		42		-
General and administrative		1,097		1,314		1,187

Total share-based compensation		1,940		1,946		1,673

Share-based payment plan for employees and directors:

The Company has granted options and restricted stock units ("RSUs") for a total of 990,201 ordinary shares.

As of December 31, 2023, 861,255 ordinary shares of the Company were still available for a future grant.

Any options or RSUs, which are forfeited or not exercised before expiration, become available for future grants.

Options granted under the Company's 2003 Israeli Share Option Plan ("The Plan") are exercisable in accordance with the terms of the Plan, within 5-10 years from the date of grant, against payment of an exercise price or cashless exercise. The options generally vest over a period of 3-4 years.

In March 2014, the Company adopted and obtained shareholder approval for its 2014 Equity Incentive Plan (the “2014 Plan”). Options and RSU's granted under the Company's 2014 Plan are exercisable in accordance with the terms of the Plan. Options are exercisable within 5-10 years from the date of grant, against payment of an exercise price or cashless exercise and share units are granted immediately upon vesting of the RSU's. The options and the RSU's generally vest over a period of 1-4 years.

Share options activity:

The following table lists the number of share options, the weighted average exercise prices of share options and changes that were made in the option plan to employees and directors

	2023					2022					2021
	Number of options			Weighted Average Exercise price		Number of options			Weighted Average Exercise price		Number of options			Weighted Average Exercise price

Outstanding Options at beginning of year		764,767			30.44		537,288			44.45		513,973			45.85
Options Granted		346,950			11.87		320,775			14.25		53,970			37.52
Options Exercised		-			-		(807	)		12.23		(536	)		20.16
Options Forfeited and/or expired		(154,230	)		57.55		(92,489	)		55.58		(30,119	)		56.91

Outstanding options at end of year		957,487			19.34		764,767			30.44		537,288			44.45

Option's Exercisable at end of year		462,045			26.25		373,681			46.18		333,618			58.38

The following table summarizes information about share options outstanding:

	Options outstanding as of December 31, 2023
Range of exercise prices ($ )	Number of options		Weighted Average Remaining contractual life		Weighted average exercise price

8.26-9.64		55,950		9.85		8.44
11.89-14.42		711,124		7.89		13.20
26.88-37.52		125,535		5.62		35.99
42.14-67.06		64,878		1.85		63.84
Total		957,487		7.29		19.34

	Options outstanding as of December 31, 2022
Range of exercise prices ($ )	Number of options		Weighted Average Remaining contractual life		Weighted average exercise price

12.25-14.42		470,693		7.84		13.60
26.88-37.52		145,354		6.43		35.95
42.14-67.06		68,662		2.85		63.94
90.23-96.32		80,058		0.91		90.65
Total		764,767		6.40		30.44

The following table summarizes information about RSU's outstanding:

	RSU's 2023			RSU's 2022			RSU's 2021

Outstanding at beginning of year		42,013			14,581			10,655
Granted		9,100			39,286			8,992
Forfeited		(941	)		(27	)		(215	)
Vested		(17,458	)		(11,827	)		(4,851	)

Outstanding at the end of the period		32,714			42,013			14,581

The fair value of the options and RSU's granted to employees and directors at the grant date for the years ended December 31, 2023, 2022 and 2021 was $2,320, $2,970 and $1,392 respectively.

The options and RSU’s of the Company are managed by a trustee.

On March 4, 2021, the Company's Board of Directors approved the grant of: (a) 34,013 options to purchase ordinary shares and 5,669 RSU's under the "2014 Share Incentive Plan" to its CEO, officers and board members of the Company at a fair value of $663 and $196, respectively, and (b) 19,958 options to purchase ordinary shares and 3,324 RSU's under the "2014 Share Incentive Plan" to its employees at a fair value of $417 and $116, respectively. The options are exercisable for an exercise price of $ 37.52 per share.

Over the second quarter of 2022, the Company’s Board of Directors approved the grant of 292,203 options to purchase the Company’s ordinary shares, for an exercise price of $ 14.42 per share as well as 39,286 restricted share units (“RSU’s”) to its CEO, officers and employees. The fair value of the options and RSU’s as of the grant date, was estimated at $2,314 and $498 respectively.

The above-mentioned grant includes the grant of 151,786 options to purchase the Company’s ordinary shares and 39,286 restricted share units (“RSU’s”) to the directors and the CEO of the Company which are required to be approved by the Company’s General meeting as well. The fair value of the options and RSU’s, as of the approval date, was estimated at approximately $1,171 and $498, respectively.

On July 19, 2022, the Company’s Shareholders General meeting approved the abovementioned grants (Note 19) to the directors and the CEO, the compensation terms of Mr. Ofer Gonen as the Company’s new Chief Executive Officer, which terms will be effective as of July 1, 2022 and the termination terms for the previous CEO.

On August 18, 2022, the Company’s Shareholders General meeting approved the compensation terms and grant of 28,572 options to the Chairman of the Board of Directors which approved earlier by the board. The fair value of the options as of the grant date was estimated at $284.

On February 15, 2023, the Company's Board of Directors approved the grant of 130,600 options to purchase ordinary shares and 9,100 RSU's under the "2014 Share Incentive Plan" to employees, officers, board members, CEO and some consultants at fair value of $1,012 and $117, respectively. The share options vest over a period of 1-4 years and the options are exercisable for an exercise price of $ 13.32 per share.

On April 3, 2023, the Company's Board of Directors approved the grant of 160,400 options to purchase ordinary shares under the "2014 Share Incentive Plan", for an exercise price of $11.89 and $11.91 per share to management and board members of the Company. The share options vest over a period of 1-4 years. The fair value of the options granted, as of the grant date, was estimated at approximately $884.

On May 31, 2023 the Shareholders of the Company approved the increase by 1,000,000 in the number of ordinary shares available for issuance under the Company’s 2014 Equity Incentive Plan.

On May 31, 2023 the Shareholders of the Company approved the extension to the exercise period of options which were granted to certain of the company’s directors on April 23, 2020 for an additional five years, until April 23, 2030. According to this extension, an expense of $146 was recognized.

On August 15, 2023, the Company's Board of Directors approved the grant of 7,200 options to purchase ordinary shares under the "2014 Share Incentive Plan", for an exercise price of $ 9.63 per share to a board member of the Company. The share options vest over a 1 year. The fair value of the options granted, as of the grant date, was estimated at approximately $42.

10.

On November 20, 2023, the Company's Board of Directors approved the grant of 48,750 options to purchase ordinary shares under the "2014 Share Incentive Plan", for an exercise price of $ 8.78 and $8.13 per share to an officer and a consultant of the Company. The share options vest over a period of 1-4 years. The fair value of the options granted, as of the grant date, was estimated at approximately $265.

The fair value of the Company's share options granted to employees and directors for the years ended December 31, 2023, 2022 and 2021 was estimated using the binomial option pricing models using the following assumptions:

	December 31
	2023		2022		2021
Dividend yield (%)		0		0		0
Expected volatility of the share prices (%)		61-77		59-77		55-78
Risk‑free interest rate (%)		2.1-5.36		2.1-5.2		0.1-1.5
Early exercise factor (%)		100-150		100-150		100-150
Weighted average share prices (Dollar)		10.71		13.22		36.33

Measurement inputs include the share price on the measurement date, the exercise price of the instrument, expected volatility (based on the weighted average volatility of the Company’s shares, over the expected term of the options), expected term of the options (based on general option holder behavior and expected share price), expected dividends, and the risk-free interest rate (based on government debentures).

Share-Based Compensation (Schedule of Information About Share Options Outstanding) (Details)	12 Months Ended
	Dec. 31, 2023 shares $ / shares	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options \| shares	957,487	764,767	537,288	513,973
Weighted Average Remaining contractual life	7 years 3 months 14 days	6 years 4 months 24 days
Weighted average exercise price \| $ / shares	$ 19.34	$ 30.44	$ 44.45	$ 45.85
8.26-9.64 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options \| shares	55,950
Weighted Average Remaining contractual life	9 years 10 months 6 days
Weighted average exercise price \| $ / shares	$ 8.44
11.89-14.42 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options \| shares	711,124
Weighted Average Remaining contractual life	7 years 10 months 20 days
Weighted average exercise price \| $ / shares	$ 13.2
26.88-37.52 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options \| shares	125,535
Weighted Average Remaining contractual life	5 years 7 months 13 days
Weighted average exercise price \| $ / shares	$ 35.99
42.14-67.06 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options \| shares	64,878
Weighted Average Remaining contractual life	1 year 10 months 6 days
Weighted average exercise price \| $ / shares	$ 63.84
12.25-14.42 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options \| shares		470,693
Weighted Average Remaining contractual life		7 years 10 months 2 days
Weighted average exercise price \| $ / shares		$ 13.6
26.88-37.52 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options \| shares		145,354
Weighted Average Remaining contractual life		6 years 5 months 4 days
Weighted average exercise price \| $ / shares		$ 35.95
42.14-67.06 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options \| shares		68,662
Weighted Average Remaining contractual life		2 years 10 months 6 days
Weighted average exercise price \| $ / shares		$ 63.94
90.23-96.32 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options \| shares		80,058
Weighted Average Remaining contractual life		10 months 28 days
Weighted average exercise price \| $ / shares		$ 90.65

Inventories (Tables)

12 Months Ended

Dec. 31, 2023

Classes of current inventories [abstract]

Schedule of inventories

	December 31,
	2023		2022

Raw materials		995		913
Finished goods		*1,851		1,050

		2,846		1,963

*Including write-down of $326

Share-Based Compensation (Schedule of Expense Recognized) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation	$ 1,940	$ 1,946	$ 1,673
Cost of revenues [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation	271	184	153
Research and development [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation	485	406	333
Selling and marketing [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation	87	42	0
General and administrative [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation	$ 1,097	$ 1,314	$ 1,187

Inventories

12 Months Ended

Dec. 31, 2023

Classes of current inventories [abstract]

Inventories

Note 7:

Inventories

	December 31,
	2023		2022

Raw materials		995		913
Finished goods		*1,851		1,050

		2,846		1,963

*Including write-down of $326

Other Receivables Short Term

12 Months Ended

Dec. 31, 2023

Trade and other current receivables [abstract]

Other Receivables- Short Term

Note 8:

Other Receivables- Short Term

	December 31,
	2023		2022

Government authorities		322		193
Income receivables		397		170
Prepaid expenses and other		722		287

		1,441		650

Subsequent events (Narrative) (Details) ₪ / shares in Units, $ / shares in Units, $ in Thousands					1 Months Ended
	Mar. 06, 2024 $ / shares shares	Feb. 07, 2023 shares	Sep. 26, 2022 ₪ / shares shares	Mar. 07, 2022 shares	Feb. 26, 2024 $ / shares	Jan. 31, 2024 ILS (₪)	Jan. 31, 2024 USD ($)	Feb. 15, 2023	Jan. 01, 2024 m²	Dec. 31, 2023 ₪ / shares
Disclosure of non-adjusting events after reporting period [line items]
Number of common shares issued		1,964,286	1,082,223	744,048
Exercise price of warrants \| ₪ / shares			₪ 13.475							₪ 0.0015312
Employees, Officers, Board Members CEO and Consultants [Member]
Disclosure of non-adjusting events after reporting period [line items]
Vesting period								1-4 years
Subsequent Events [Member]
Disclosure of non-adjusting events after reporting period [line items]
Area of office \| m²									380.21
Number of common shares issued	311,022
Number of restricted stock units issued	30,482
Term of lease						2 years	2 years
Additional term of lease						3 years	3 years
Number of pre funded warrants exercised	37,106
Exercise price of warrants \| $ / shares	$ 13.475
Subsequent Events [Member] \| Employees, Officers, Board Members CEO and Consultants [Member]
Disclosure of non-adjusting events after reporting period [line items]
Annual fee of lease agreement						₪ 437	$ 120
Exercise price per share \| $ / shares					$ 12.73
Vesting period					1-4 years

Severance Pay Liability, Net

12 Months Ended

Dec. 31, 2023

Disclosure of defined benefit plans [abstract]

Severance Pay Liability, Net

Note 16:

Severance Pay Liability, Net

The Company has liabilities for severance pay for its employees in Israel and in several EU jurisdictions. The Company’s liability for employee benefits is based on local laws, valid labor agreements, the employee’s salary and the applicable terms of employment, which together generate a right to severance compensation. Post‑employment employee benefits are partially financed by deposits with defined contribution plans, as detailed below.

The Israeli Severance Pay Law, 1963 (“Severance Pay Law”), specifies that Israeli employees are entitled to severance payment, following the termination of their employment.

Under the Severance Pay Law, the severance payment is calculated as one month salary for each year of employment, or a portion thereof. Under Section 14 of the Severance Pay Law (“Section 14”), employees are entitled to have monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf to their insurance funds. Payments in accordance with Section 14 release the Company from the liability for any future severance payments in respect of those employees.

The majority of the Company’s liability for severance pay is covered by Section 14. Accordingly, the Company does not recognize any liability for severance pay due to these employees and the deposits under Section 14 are not recorded as an asset in the Company’s balance sheet. These contributions for compensation represent defined contribution plans. The Company recognizes liability for severance pay due to its employees in EU in accordance with local laws and its Israeli employees which are not under Section 14.

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2023

Earnings per share [abstract]

Schedule of details of number of shares and loss used in computation

Year ended December 31
2023					2022					2021
Weighted average number of shares		Loss			Weighted average number of shares		Loss			Weighted average number of shares		Loss

	9,013,144		(6,716	)		4,987,069		(19,599	)		3,892,068		(13,551	)

Schedule of net profit (loss) per share from continuing and discontinued operations

	Year ended December 31
	2023			2022			2021

Basic and diluted loss per share:		(0.75	)		(3.93	)		(3.48	)

Balances and Transactions With Related Parties and Key Officers (Schedule of Balances of Related Parties) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Related Party [Member]
Disclosure of transactions between related parties [line items]
Payables	$ 0	$ 177
Directors [Member]
Disclosure of transactions between related parties [line items]
Payables	$ 83	$ 130

Leases (Schedule of disclosures of lease liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis of operating lease payments [line items]
Repayment of leases liabilities	$ (778)	$ (701)	$ (693)
Financial expenses	274	102
Lease liability Balance as of December 31,	6,350	846
Lease liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Balance as of December 31,	1,378	1,990
Repayment of leases liabilities	(778)	(701)
Effect of changes in exchange rates	(17)	(210)
New finance lease obligation recognized	6,825	117
Adjustments for indexation	81	83
Financial expenses	274	101
Disposals-Termination of leases	(1,052)	(2)
Balance as of December 31,	6,711	1,378	1,990
Current maturities of long-term leases	(361)	(532)
Lease liability Balance as of December 31,	6,350	846
Lease liabilities [Member] \| Buildings [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Balance as of December 31,	1,199	1,691
Repayment of leases liabilities	(588)	(477)
Effect of changes in exchange rates	(19)	(182)
New finance lease obligation recognized	6,460	0
Adjustments for indexation	78	(74)
Financial expenses	257	93
Disposals-Termination of leases	(1,041)	0
Balance as of December 31,	6,346	1,199	1,691
Current maturities of long-term leases	(180)	(399)
Lease liability Balance as of December 31,	6,166	800
Lease liabilities [Member] \| Motor vehicles [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Balance as of December 31,	179	299
Repayment of leases liabilities	(190)	(224)
Effect of changes in exchange rates	2	(28)
New finance lease obligation recognized	365	117
Adjustments for indexation	3	(9)
Financial expenses	17	8
Disposals-Termination of leases	(11)	(2)
Balance as of December 31,	365	179	$ 299
Current maturities of long-term leases	(181)	(133)
Lease liability Balance as of December 31,	$ 184	$ 46

Equity

12 Months Ended

Dec. 31, 2023

Disclosure of classes of share capital [abstract]

Equity

Note 19:

Equity

Share capital:

	December 31
	2023		2022

Authorized number of shares		20,000,000		12,857,143
Issued and outstanding number of shares		9,221,764		7,240,020

An ordinary share confers upon its holder(s) a right to vote at the general meeting, a right to participate in distribution of dividends, and a right to participate in the distribution of surplus assets upon liquidation of the Company.

	b.	Movement in share capital:

During 2021, 2022 and 2023 the Company issued additional 4,852, 41,395 and 17,458 ordinary shares for each year upon vesting of outstanding RSU’s, respectively.

On November 28, 2022, at the Company’s extraordinary general meeting of shareholders, its shareholders approved:

(a)

An increase of the Company’s authorized share capital from NIS 500,000, consisting of 50,000,000 ordinary shares, per value NIS 0.01 per share to NIS 900,000 consisting of 90,000,000 ordinary shares, per value NIS 0.01 per share.

(b)

On December 5, 2022, the Company’s board of directors approved a reverse split of 1-for-7 ratio. The reverse split went effective on December 20, 2022.

No fractional shares were issued as a result of the reverse share split. Instead, such shares were rounded up to the next whole number of shares. The reverse share split affected all shareholders uniformly and did not alter any person’s percentage interest in our outstanding ordinary shares, except for negligible adjustments that may have resulted from the treatment of fractional shares.

In connection with the reverse share split, The Company also amended and reduced the authorized number of ordinary shares from 90,000,000 to 12,857,143, which reflected a reduction at the same 1-for-7 ratio as the reduction to the number of issued and outstanding ordinary shares.

Concurrently, the par value of the Company’s ordinary shares was increased proportionately, from NIS 0.01 per share to NIS 0.07 per share, in order to maintain the same overall authorized share capital under our Amended and Restated Articles of Association.

On May 31, 2023 the Shareholders of the Company approved an amendment to Article 6 of the Company’s Amended and Restated Articles of Association, which increased the Company’s authorized share capital from 900,000 NIS consisting of 12,857,143 ordinary shares par value NIS 0.07 to NIS 1,400,000, consisting of 20,000,000 ordinary shares, par value NIS 0.07 per share.

Financial transactions:

On March 7, 2022, the Company completed a public offering in total of 744,048 new ordinary shares which were issued in consideration to offering price of $13.44 per share. The net proceeds were $8,653, after deducting commissions and other offering expenses. In addition, on March 22, 2022 the underwriters exercised their options to purchase an additional 89,012 ordinary shares at the same public offering price. The net consideration to the Company, less underwriting discounts and commissions was at additional of $1,021.

As part of the above- mentioned public offering, certain entities affiliated with CBI purchased 208,334 of ordinary shares at the public offering price.

On September 26, 2022, the Company completed a registered direct (the “RD”) offering in an aggregate amount of $13,257 represent a combine purchase price of $12.25 for issuance of 1,082,223 ordinary shares and 1,082,223 warrants that become exercisable on November 28, 2022, at an exercise price of $13.475 per ordinary share which will expire in four years (see also note 25.3).

The warrants issued have been classified as a non-current financial liability due to a net share settlement provision and as they can be settled in cash on the occurrence of Fundamental Transaction as determined in the agreement. This liability was initially recognized at its fair value on the date the contract was entered into and is subsequently accounted for fair value at each balance sheet date and recorded through profit and loss.

The fair value of the warrants has been evaluated with the assistance of external independent valuator and was computed based on then current price of the shares, a risk-free interest rate of 4.37% and an average standard deviation of 68%.

The net proceeds from this offering in the amount of $11,698 have been received on September 28, 2022. The issuance expenses related to the non-current financial liability were recorded through profit and loss and the issuance expenses related to the issuance of shares recorded as a deduction from the proceeds in equity.

Concurrently, on October 6, 2022, the Company entered into a Private Issuance Purchase Equity agreement (the “PIPE”) with several purchasers, in connection with the offering of 1,407,583 unregistered pre-funded warrants to purchase up to 1,407,583 ordinary shares and 1,407,583 warrants to purchase up to 1,407,583 ordinary shares. Pre-Funded warrants become exercisable on November 28, 2022, at an exercise price of $0.007 per ordinary share and the warrants would be also exercisable upon the Authorized Share Increase Date at an exercise price of $13.475 per ordinary share and expire in four years.

The Pre-Funded warrants and warrants issued have been classified as a non-current financial liabilities due to a net share settlement provision and they can be redeemed in cash on the occurrence of Fundamental Transaction as determined in the agreement. The initial fair value of the financial liabilities issued in the transaction was approximately $20,788, which comprised of: 1. The warrants which were valuated by Black and Sholtes model based on the current price of the shares and a risk-free interest rate of 4.26%, and 2. The pre-funded warrants which were valued in an amount which is approximate its share price upon their issuance.

The consideration received from this transaction was $17,233. As the fair value on initial recognition of the warrants differs from the transaction price, the difference, represents the First day loss at the amount of $3,555, and has been allocated to the warrants with respect to this transaction and is amortized on a straight line basis over the term of the warrants.

The net proceeds from this offering amounted to approximately $15,920. The issuance expenses were recorded through profit and loss.

During December 2022, the 1,407,583 pre-funded warrants were exercised into ordinary shares.

Upon closing of the RD and PIPE Offerings, the Company also issued the placement agent up to 124,491 warrants to purchase up to 124,491 ordinary Shares. The warrants have substantially the same terms as the RD and PIPE Warrants, except that the placement agent’s warrants have an exercise price equal to $15.312 per share (which represents 125% of the offering price per ordinary Share in the offerings). The Fair value of the placement agent’s options was recorded as an issuance expenses through profit and loss and as a deduction from proceed in equity based on the financial treatment of both RD and PIPE offering and in accordance with their part.

On February 7, 2023, the Company completed a registered direct (the “RD”) offering of 1,964,286 new ordinary shares which were issued in consideration to offering price of $14.0 per share. The gross proceeds were $27,500, before deducting commissions and other offering expenses in the amount of $2,031.

Leases (Tables)

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Schedule of amounts recognized in profit or loss and in the statement of cash flows

	Year ended December 31,
	2023		2022

Interest expense on lease liabilities		274		102
Depreciation expenses		565		537
Cash outflow for leases		778		701

Schedule of carrying amounts of right-of-use assets and movement

	Buildings			Motor vehicles			Total
Cost
Balance as of January 1, 2023		2,341			550			2,891
New leases		6,460			407			6,867
Adjustments for indexation		78			3			81
Disposals		(2,368	)		(308	)		(2,676	)

Balance as of December 31, 2023		6,511			652			7,163

Accumulated depreciation
Balance as of January 1, 2023		1,342			334			1,676
Depreciation and amortization		334			231			565
Capitalized to Leasehold improvements		59			-			59
Disposals		(1,527	)		(308	)		(1,835	)

Balance as of December 31, 2023		208			257			465

Depreciated cost
Balance as of December 31, 2023		6,303			395			6,698

	Buildings		Motor vehicles			Total
Cost
Balance as of January 1, 2022		2,267		654			2,921
New leases		-		125			125
Adjustments for indexation		74		9			83
Disposals		-		(238	)		(238	)

Balance as of December 31, 2022		2,341		550			2,891

Accumulated depreciation
Balance as of January 1, 2022		1,028		345			1,373
Depreciation and amortization		314		225			539
Disposals		-		(236	)		(236	)

Balance as of December 31, 2022		1,342		334			1,676

Depreciated cost
Balance as of December 31, 2022		999		216			1,215

Schedule of maturity analysis of the Group's lease liabilities

	Buildings			Motor vehicles			Total

Balance as of January 1, 2023		1,199			179			1,378
Repayment of leases liabilities		(588	)		(190	)		(778	)
Effect of changes in exchange rates		(19	)		2			(17	)
New finance lease obligation recognized		6,460			365			6,825
Adjustments for indexation		78			3			81
Financial expenses		257			17			274
Disposals-Termination of leases		(1,041	)		(11	)		(1,052	)
Balance as of December 31, 2023		6,346			365			6,711

Current maturities of long-term leases		(180	)		(181	)		(361	)
Lease liability Balance as of December 31, 2023		6,166			184			6,350

	Buildings			Motor vehicles			Total

Balance as of January 1, 2022		1,691			299			1,990
Repayment of leases liabilities		(477	)		(224	)		(701	)
Effect of changes in exchange rates		(182	)		(28	)		(210	)
New finance lease obligation recognized		-			117			117
Adjustments for indexation		74			9			83
Financial expenses		93			8			101
Disposals-Termination of leases		-			(2	)		(2	)
Balance as of December 31, 2022		1,199			179			1,378

Current maturities of long-term leases		(399	)		(133	)		(532	)
Lease liability Balance as of December 31, 2022		800			46			846

Short-term and restricted bank deposits (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure Of Short Term Bank Deposits [Abstract]

Schedule of short-term bank deposits

	December 31
	2023		2022

Restricted bank deposits (1)		167		-
USD Bank deposits (2)		29,675		-

		29,842		-

(1)

Restricted bank deposits which are primarily used as security for the Company’s office leases.

(2)

The USD deposits bear annual interest of 6.26%-6.55% for the period of 91-365 days for 2023.

Other Receivables Short Term (Tables)

12 Months Ended

Dec. 31, 2023

Trade and other current receivables [abstract]

Schedule of other short term receivables

	December 31,
	2023		2022

Government authorities		322		193
Income receivables		397		170
Prepaid expenses and other		722		287

		1,441		650

Balances and Transactions With Related Parties and Key Officers (Schedule of Compensation of Officers of Company) (Details)
$ in Thousands

12 Months Ended

Dec. 31, 2023

USD ($)

Officers

Dec. 31, 2022

USD ($)

Officers

Dec. 31, 2021

USD ($)

Officers

Disclosure of transactions between related parties [abstract]

Short-term employee benefits

^[1],[2]

$ 2,084

$ 2,880

$ 1,788

Share-based compensation

757

797

518

Compensation of officers

$ 2,841

$ 3,677

$ 2,306

Number of officers | Officers

^[3]

[1]	In December 2007, the Company's board of directors approved one‑time bonus payments to the Chief Medical Officer in the amounts of $ 120, which was recorded in profit and loss in December 2022 upon achieving marketing approval in the United States.
[2]	One-time expenses amounted $309 for the year ended December 31, 2022, are associated with the management changes.
[3]	During 2023 two key officers were replaced. At the end of 2023 the total key officers consist of six officers.

Other Receivables- Long Term

12 Months Ended

Dec. 31, 2023

Trade and other non-current receivables [abstract]

Other Receivables- Long Term

Note 9:

Other Receivables- Long Term

	December 31,
	2023		2022

Income receivables		50		180
Prepaid expenses		183		-

		233		180